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mistake! I believe if there were no hope for me I would crack up, but ifl were lucky I would end it 
all first. They say where there is life there is hope. The doctors say they will treat me only as long 
as I am repigmenting. At least fully dressed, with long pants and long-sleeved shirts, I look almost 
like one of you humans. To be rid ofvitiligo would be like being reborn for me, to be normal and 
happy." 
(A letter from an anonymous vitiligo sufferer published in Clin. 
Dermatol.; 1997; 15: 886) 
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An in vitro investigation of the effect of KUV A (Khellin and UV A) on Normal and 
Transformed Human Melanocytes 
Gadija Carlie 
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The problematic and numerous side effects of PUV A (psoralen and UV A) and other treatments 
currently in use for vitiligo, have justified the search for an alternative treatment. In this study, the 
use ofkhellin, a naturally occurring furochromone, which is similar in structure to psoralens, is 
explored as an alternative treatment for vitiligo. When khellin is combined with UV A (KUY A), it 
is reported to repigment vitiligo skin as effectively as PUV A photochemotherapy, but without the 
adverse effects reported with PUV A. The exact mechanism for khellin-induced repigmentation is 
still to be determined and no cell biological studies have yet been done to elucidate its mechanism 
of action. The specific aim of this project was to set up an in vitro tissue culture system to 
determine the direct effects ofkhellin, UV A and KUV A on melanocyte proliferation and 
pigmentation. 
Studies were carried out on cultures of a human melanoma cell line (Mel-1 ), normal human 
melanocytes and 3T3 mouse fibroblasts . Cell proliferation assays revealed that the proliferation of 
melanoma cells and melanocytes were increased after exposure to khellin for four days at 
concentrations ranging from lnM to 0.5mM. A peak of proliferation was obtained at O.OlmM 
khellin, which stimulated proliferation of melanoma cells and melanocytes by 2.3 5-fold and 2.1-
fold, respectively. In contrast, khellin decreased proliferation of fibroblasts over the entire 
concentration range tested. At concentrations of0.5mM and above, khellin was cytotoxic to both 
melanocytic cells and fibroblasts. Cytotoxic assays revealed that lmM khellin was equally 
cytotoxic to both melanoma cells and fibroblasts. In addition, these assays revealed that the 
proliferative response observed with O.OlmM and O. lmM khellin, did not mask an underlying 
cytotoxic effect. Exposure to single doses of UV A between 150-280mJ/cm
2
, increased proliferation 
of melanoma cells with maximal proliferation at 250mJ/cm
2
, while the proliferation of normal 
xiv 
xv 
melanocytes and fibroblasts were unaffected by this UV A dose. More significantly than khellin or 
UV A alone, the treatment with the combination of khellin and UV A (KUV A) stimulated 
proliferation of the melanocytic cells. The combination ofO.OlmM khellin plus a single dose of 
UV A at 250mJ/cm
2 was the most effective treatment. KUV A combination treatments were found 
to be more cytotoxic to the fibroblasts than khellin or UV A alone. 
To test the effect ofkhellin, UV A and KUV A on melanogenesis, standard radiometric assays were 
carried out. The combination ofkhellin and UV A enhanced melanogenesis of the melanocytic cells 
more significantly than khellin alone or UV A alone. The dose of 0.0lmM khellin plus 250mJ/cm
2 
UV A (maximal proliferative dose) increased melanogenesis of the melanocytes by 290% above the 
untreated control melanocytes. 
To determine whether khellin and KUV A act by increasing levels of melanogenic proteins, western 
blot analyses were carried out. The results revealed that there were no differences in the amounts of 
TRP-2 and tyrosinase in the melanocytic cells treated with khellin alone. In contrast, those treated 
with KUV A ( or UV A alone) had increased levels of the glycosylated form of the enzymes and also 
possibly had increased levels of the de nova form of the enzymes. These results suggest that UV A 
might be enhancing glycosylation of melanogenic enzymes and provides a novel insight into the 
possible mechanism for UV A-induced melanogenesis. The results also revealed that 3T3 
fibroblasts expressed the non-glycosylated form of TRP-2, as described by others. 
In conclusion, this study suggests a model in which khellin acts directly on melanocytic cells by 
acting as a mitogen and a melanogen at non-toxic concentrations. Khellin possibly increases 
melanogenesis by acting post-translationally or antagonizing or removing an inhibitor of the 
melanogenic pathway. The melanocyte-specific effect ofkhellin and even more so KUV A, seems 
to suggest that khellin acts along the signal transduction pathways which increases both 
proliferation and melanogenesis in melanocytes, possibly via endothelin-1 pathways. 
Key words: vitiligo/ khellin/ KUV A/ ultraviolet A/ cell proliferation/ melanogenesis/ western 







Vitiligo is a common hypopigmentary disorder of the skin and sometimes hair, with serious 
psychological and social consequences (Kent and Al' Abdie, 1996 a, b). Vitiligo affects 
approximately 1 to 5% of the world's population (average of 1 in 200 individuals), and incidence 
levels are reported to be as high as 8% in India and Pakistan (Nordlund, 1997; Schwartz and 
Janniger, 1997). This disease may occur at any age and affects both male and female sex equally. It 
is not certain whether vitiligo is a genetic disease. However, it is known that the chance of 
developing vitiligo is 4-5 times higher in those who have close biological relatives who suffer from 
this disease, compared to the general population (Das et. al., 1985). Furthermore, it has been shown 
that vitiligo is linked to several genes, but the inheritance pattern of this disease did not follow the 
typical Mendelian genetics or X-linked patterns (Mehta et. al., 1973; Hafez et. al., 1983; Majumder 
et. al., 1993; Nath et. al., 1994) 
The aetiology of this disease is still unknown. What is known, is that the melanocytes (pigment-
producing cells) in the epidermis of the skin, progressively disappear until they are completely 
absent in the vitiliginous lesions, as shown by histochemical (Le Poole et. al., 1992; 1993 a, b; 
1996) and ultrastructural studies (Galardi et. al. , 1993; Bartosik et. al., 1998). This results in the 
milk-white blotches on the skin, which gradually become larger as the disease progresses. Besides 
the melanocytes being progressively destroyed, the adjacent epidermal cells may also be somewhat 
altered (Bhawan et. al., 1993; Le Poole et. al., 1996), by an unknown mechanism. 
There are several treatments for vitiligo currently in use (see reviews Schwartz and Janniger, 1997 
and Kovacs, 1998), but the problematic and numerous side effects associated with these treatments 
have justified the search for an alternative treatment for vitiligo. In this study, the use ofkhellin as 
an alternative treatment for vitiligo is explored. Since melanocytes are predominantly affected in 
this disease, the focus of this study was to determine the effect ofkhellin on melanocyte 
proliferation and pigment synthesis (melanogenesis). The following review includes a general 
overview of the current understanding of the origin, development and biological functions of the 
melanocytes, as well as a description ofvitiligo pathology, vitiligo aetiology, mechanisms and 
shortcomings of current vitiligo treatments. 
2 
1.2 FUNCTIONS OF MELANIN 
The most important function of melanocytes is the synthesis of melanin, which protects the skin and 
underlying organs from photo-damage and photo-carcinogenesis (reviewed Diffey et. al., 1998). 
This protective function is brought about by melanin acting as a scavenger of toxic oxygen radicals 
and cytotoxic agents such as amines and metal ions generated within the melanocyte cytoplasm ( see 
reviews Gilchrest, 1996; Applegate and Frenk, 1995, Memoli et. al., 1997). (Figure 1.1) In 
addition, melanin in the skin and hair provides the colour, which serves as a protective colourant 
and sexual attractant within species. Besides the melanin itself having functions, it has also been 
shown that melanogenic intermediates play an important role in many physiological and 
pathological conditions, such as tissue repair/ regeneration, immune and inflammatory processes 
(Prunieras, 1986; Nordlund et. al., 1988; Slominski et. al., 1993). The indole melanogenic 
intermediates, DHI and DHICA (5,6-dihydroxyindole and 5,6-dihydroxyindole-2-carboxylic acid, 
respectively), have been shown to exhibit potent antioxidant activity (d' Ischia, 1995; Schmitz et. 
al., 1995), and therefore protect the melanocytes against harmful free radicals. 
1.3 MELANOCYTE BIOLOGY 
Mammalian melanocytes are found primarily in the basal layer of the epidermis of the skin, hair 
follicles, iris and choroid of the eye (Figure 1.2). Epidermal melanocytes extend their numerous 
dendritic processes between the neighbouring keratinocytes, and it is estimated that about 36 
keratinocytes are associated with each melanocyte in this manner. The association between a 
melanocyte and neighbouring keratinocytes is known as an epidermal-melanin unit (Figure l .2F). 
Amongst other features, this arrangement ensures that the melanocytic dendrites, which contain 
melanosomes laden with melanin, are transferred to the adjacent keratinocytes. The colour of skin 
and hair is related to the number, size, type, distribution and degradation of melanosomes, and to 
the levels of activity of melanogenic enzymes found within these melanosomes (Bessou et. al., 
1996). Further modulation of melanocyte function is brought about by intrinsic and extrinsic 
factors such as inhibitors, growth factors, hormones and ultraviolet light. 
1.3.1 Origin and differentiation of melanocytes 
When cells emerge from the neural crest during embryonic development, they enter the "migration 







FIGURE 1.1: Schematic outline of Melanogenesis highlighting the 




















































































































FIGURE 1.2: Overview of melanogenesis. A: Most melanocytes in the body originate 
embryonically from neural crest cells that emigrate out of the dorsal surface of the 
neural tube, become committed to melanocytes at the staging area, and migrate 
selectively along the dorsal/lateral pathway over the somites. B: Melanocyte 
precursors, melanoblasts, target accurately to specific sites throughout the body. In the 
skin, these cells eventually reside in the basal epithelial layer of the interfollicular 
epidermis (1) and in the germinative bulb of the hair-follicle (2). C: In the ears, they 
eventually reside in the stria vascularis and the modiolus of the cochlea, in the 
vestibular organ. D: In the eye, they eventually reside in the uveal tract composed of 
the choroid, ciliary bodies and iris. E: In the brain they reside in the leptomeninges 
composed of the meninges covering the ventrolateral surfaces of the medulla oblongata 
and upper cervical cord (see arrows). F: Once settled into these permanent places of 
residence, the melanocyte completes differentiation and manufactures melanin. A 
diverse array of melanocyte specific genes are regulated. The corresponding gene 
products of enzymatic and structural proteins undergo a complete orchestration of 
translocation in the cytoplasm to form the functional premelanosome. G: In 
premelanosomes, tyrosine undergoes a series of biochemical alterations to form various 
melanin polymers. Eventually, in the skin, the melanosomal product is shuttled down 
the dendrites and transferred to the neighbouring keratinocytes (F). The partnership 
of an epidermal melanocyte and a neighbouring group of keratinocytes is known as the 
epidermal-melanin unit. Each epidermal melanocyte secretes melanosomes into a 
definite number of neighbouring keratinocytes (F). (modified from Boissy and 
Nordlund, 1997) 
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Erickson, 1986). From here the neural crest cells, which are destined to become melanocytes, 
migrate laterally beneath the ectoderm along the dorsolateral pathway. At this stage they are called 
melanoblasts. Melanoblasts are identified by the presence ofTRP-2 (tyrosine-related protein-2), 
which is the first melanocyte lineage-specific protein to be expressed in melanocytes (Steel et. al., 
1992). These melanoblasts migrate throughout the mesenchyme, home into specific target sites and 
eventually differentiate into active melanocytes, characterised by dendrification (Preston et. al., 
1987), detectable tyrosinase activity (Pomerantz, 1966; Pawelek et. al., 1973) and melanin 
deposition within melanosomes (Hu et. al., 1982). 
1.3.2 Summary of melanosome formation 
Melanin is synthesized in specialized membrane-bound organelles, the melanosomes, which are 
located in the melanocyte cytoplasm. The structural components of these melanosomes provide a 
framework for the activity of the rate-limiting enzyme of melanogenesis, tyrosinase, and for 
melanin deposition (Jimbow et. al. , 1992; reviewed Hirobe, 1992; 1995). The melanosome is 
formed when Golgi-derived vesicles containing tyrosinase fuses with vesicles or dilated tubules of 
smooth endoplasmic reticulum that harbour the melanocyte structural components. The fusion of 
these two membrane compartments initiates the first stage of melanosome maturation. During their 
maturation, these melanosomes develop into either phaeomelanin (red-yellow pigment)- or 
eumelanin (black/brown pigment)-producing organelles. Hence, melanosomes in which these are 
produced are called eumelanosomes and phaeomelanosomes, respectively. Eumelanosomes tend to 
be ellipsoidal with a regular internal matrix, whereas the spherically-shaped phaeomelanosomes 
have an amorphous interior. Environmental changes, such as exposure to ultraviolet light, may alter 
the melanosomal matrix proteins and result in the eventual deposition of melanin within the 
melanosomes, which are controlled by a number of regulatory melanogenic proteins. 
1.3.3 Melanin synthesis 
Eumelanins are black to brown and insoluble in most solvents, whereas phaeomelanins are yellow 
to reddish-brown and alkali-soluble (Ito and Fujita, 1985). At least three melanogenic enzymes are 
involved in the production ofblack/brown melanin: tyrosinase, tyrosine-related protein-I (TRP-1) 
and tyrosine-related protein-2 (TRP-2). The starting material for the melanogenic pathway is the 
amino acid, tyrosine (see Figure 1.3). The first two steps of this pathway are common to both eu-
and phaoemelanin synthesis, and are catalyzed by the enzyme, tyrosinase. Tyrosinase initiates 
melanin synthesis by catalysing the hydroxylation of tyrosine to DOPA (3,4-dihydroxy-
phenylalanine) and the oxidation of DOPA to DOP Aquinone. 
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FIGURE 1.3: Schematic diagram of the mammalian melanin biosynthetic 
pathway, from del Marmol and Beerman, 1996). Starting material is the 
amino acid, tyrosine, and enzymatic reactions attributed to tyrosinase, TRP-1 
and TRP-2. 
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At this point of the eurnelanogenic pathway, the highly reactive intermediate, DOPA-quinone, 
undergoes a rapid cyclization and rearrangement to sequentially form the indole ring structures 
leucodopachrome, which is then autocatalytically converted to dopachrome, without the need of a 
catalytic enzyme. Thereafter, DOPAchrome is converted into 5,6-dihydroxyindole (DHI) either by 
a spontaneous decarboxylation or enzymatically, under the influence of DOP Achrome tautomerase 
(DCT) (E.C. 5.3.2.3). DCT catalyses the conversion ofDOPAchrome into 5,6-dihydroxyindole-2-
carboxylic acid (DHICA) (Pawelek et. al. , 1991). Tyrosinase-related protein-2 has been shown to 
have DCT activity (Tsukamoto et. al., 1992), and thus their names are used synonymously. 
A third enzymatic reaction catalyzed by tyrosinase is the oxidation of 5,6-dihydroxyindole (DHI) to 
indole-5,6- quinones (Komer and Pawelek, 1982). Furthermore, TRP-1 has been shown to exhibit 
DHICA oxidase activity, which converts DHICA into 5,6-quinone 2-carboxylic acid (Kobayashi et. 
al., 1994 a, b). However, in contrast to this result, Boissy et. al. (1997), reported that human TRP-1 
does not use DHICA as a substrate for oxidation, but murine TRP-1 does. Finally, the quinonic 
intermediates from OHi and DIIlCA conversions form the eumelanin (brown/black) polymers. 
1.4 MELANOCYTES OF THE HAIR FOLLICLE 
There are two types of hair follicle melanocytes (see Figure 1.4) (reviewed Starrico, 1959; Tobin 
and Bystryn, 1996; reviewed Castanet and Ortonne, 1997), which differ in their location, size, 
dendricity and degree of pigmentation. They are: ( 1) dendritic, pigmented melanocytes located in 
the hair-bulb, also known as active melanocytes; and (2) non-dendritic and amelanotic melanocytes, 
located predominantly in the outer root sheath and, to a minor extent in the hair bulb. These 
amelanotic melanocytes, also known as inactive melanocytes, do not produce melanin and therefore 
do not react with antibodies to tyrosinase, TRP-1 and TRP-2 melanogenic proteins (Horikawa et. 
al. , 1996). 
The function of hair follicle melanocytes is the same as epidermal melanocytes, and that is to 
produce melanin and provide colour to the hair and skin, respectively. The main difference 
between the epidermal melanocytes and follicular melanocytes is that the activity and proliferation 
of the follicular melanocytes are linked with the hair-follicle cycle, whereas the activity of the 
epidermal melanocytes is regulated mainly by exposure to ultraviolet light. Epidermal melanocytes 
and hair follicle melanocytes have been shown to be antigenically different (Tobin and Bystryn, 
J 
Active melanocytes: 
por~ions A and D 
Amelanotic melanocytes 













portion D: upper part of the 
bulb' 
FIGURE 1.4: Subdivision of the hair follicle according to the distribution of 
melanotic and amelanotic melanocytes. Portions A and D contain melanotic 
melanocytes while Portions B and C are populated with amelanotic melanocytes 
(from Castanet and Ortonne, 1997) 
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1996). This could thus account for the preferential destruction of hair follicle melanocytes in a 
disease like alopecia areata and of epidermal melanocytes in disease like vitiligo. The colour of 
hair arises from the transfer of the melanosomes from the hair bulb melanocytes to the keratinocytes 
in the cortex and medulla of the hair shaft. This only occurs during the anagen (growth) phase of 
the hair-cycle. This is also the phase in which the enzyme, tyrosinase, is the most active. From the 
onset of the catagen phase of the hair-cycle, changes occur within the hair follicle resulting in the 
release of the dermal papilla. Subsequently, the club hair moves towards the skin surface. Above 
the papilla, the epithelial strand is reduced to the secondary germ. When the next cycle begins, the 
secondary germ elongates, becomes invaginated by the papilla and a new bulb with melanocytes is 
formed. These melanocytes come from the reservoir of melanocytes in the outer root sheath, and 
become differentiated during their migration (Cui et. al. , 1991). 
1.5 FACTORS AFFECTING MELANOGENESIS 
There are numerous endogenous and exogenous factors that may affect skin pigmentation. A brief 
summary of those factors most concerned with this present study is presented. 
1.5.1 Growth factors 
1.5.1.1 Keratinocyte-derived growth factors 
One of the most important functions of the keratinocytes in skin pigmentation is to release 
exogenous factors into the epidermal environment after exposure to a stimulus like ultraviolet light. 
It is well established that factors such as ET-1 (endothelin-1 , Yada et. al., 1991; Imokawa et. al., 
1992; 1996; 1997), bFGF (basic fibroblast growth factor, Halaban et. al., 1988), and NGF (nerve 
growth factor, Yaar and Gilchrest, 1991), are released by keratinocytes and are involved in ensuring 
melanocyte proliferation, migration and differentiation. What is less well known is the role of these 
factors in inducing the formation of melanocyte dendritic extensions, which serve as the ' vehicle' 
for transferring of melanin to the adjacent keratinocytes. The role of melanocyte dendricity as a 
critical factor for skin pigmentation is supported by the report that in a hereditary condition called 
Griscelli-Pruneiras disease (Hara et. al., 1995), which is characterized by a severe immuno-
deficiency, scattered hypopigmented macules and silver-grey hair, the epidermal and follicular 
melanocytes, contained many mature melanin-laden melanosomes, but possessed short dendritic 
processes. This suggested that the compromised melanocytic dendrites are responsible for the 
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hypo-pigmentation, since transfer of the melanin within the mature melanosomes did not take place. 
1.5.1.2 Steel /actor: 
Steel/actor (SLF; also known as c-kit ligand, mast cell growth factor or stem cell growth factor) is 
a growth factor known to play a key role in melanocyte development and differentiation. Mutations 
of the steel gene, or of its cognate receptor ( c-kit receptor tyrosine kinase) in mice, rats, and 
humans, result in animals lacking pigments cells in vivo (Nishikawa et. al., 1991 ; Williams et. al., 
1992, Dippel et. al., 1995). It is now well established that SLF regulates melanocyte development 
in mice by supporting the survival (Murphy et. al., 1992; Wehrle-Haller and Weston, 1995), 
development and proliferation of melanoblasts along the dorsolateral pathway (Mackenzie et. al., 
1997; Guo et. al. , 1997; Kunisada et. al. , 1998), before colonizing the skin and then assisting in the 
differentiation of the melanoblasts into melanocytes (Reid et. al., 1995; Kunisada et. al., 1998). 
Furthermore, it was suggested that SLF played a role in promoting the migration of melanocytes in 
vivo. This was confirmed for the first time in a recent study by Kunisada and co-workers (1998), in 
which SLF was ectopically expressed in keratinocytes and showed that melanocytes were 
distributed to a number of sites, including the oral epithelium and footpads, where neither 
melanocytes nor their precursors were usually found. 
1.5.2 Melanocyte-stimulating hormone (MSH): 
MSH is the best-characterized hormone that is involved in regulation of mammalian pigmentation 
(reviewed Furumura et. al., 1996 and Luger et. al., 1997). MSH affects both the proliferation of 
melanocytes (Abdel-Malek et. al., 1992 a, b; 1995; Aroca et. al., 1993; Halaban et. al., 1993; Swope 
et. al., 1995), as well as stimulating the production of melanins (Burchill and Thody, 1986; Abdel-
Malek, 1995). The action of a.-MSH on melanocytes in vivo and in vitro is mediated through one of 
five closely related G-protein-coupled receptors. All of these receptors are coupled to adenylate 
cyclase in vitro, and most of the melanogenic effects ofMSH could be reproduced by treatment 
with cAMP analogues in a study by (Pawelek, 1985). In vivo, a.-MSH was shown to increase 
melanogenesis by the increase in expression oftyrosinase (Levine et. al., 1991; Thody and Graham, 
1998). This is possibly by increasing Mi (micropthalmia) expression, which in turn binds to the M-
box of the tyrosinase promoter, thereby leading to the stimulation of tyrosinase expression and 
melanogenesis. This mechanism is suggested since it was demonstrated in the study of Berto lotto 
et. al. (1998), that cAMP-elevating agents increased Mi transcription and that Mi was required for 
the cAMP effect on the tyrosinase promoter. 
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1.5.3 Ultraviolet (UV) Light 
Ultraviolet (UV) radiation is one of the main external factors that stimulate human melanogenesis. 
UV radiation comprises three components: UV A (320-400nm), UVB (280-320nm) and UVC (100-
280nm). Darkening of human skin after exposure to sunlight (which is mainly UV A light) or UV 
from artificial sources is commonly known as tanning. This tanning reaction may result from a 
combination of an immediate pigment darkening (IPD) effect and a delayed pigment darkening 
(DPD) effect. The IPD effect occurs almost immediately or up to 24 hours after exposure to UV A 
light, and causes a short-term increase in pigmentation: this pigmentary response results from the 
photo-oxidation oflightly coloured or colourless melanins to the darker melanin (Willis et. al., 
1972). The DPD effect occurs 72 hours after UVB exposure and is accompanied by an increase in 
melanocyte proliferation and melanogenesis (Rosen et. al., 1987). This increase in melanogenesis 
results from an up-regulation of the activities of both tyrosinase and TRP-1 enzymes, and an 
increase in melanocyte dendrification, which ensures an increase in the transfer of melanosomes to 
the adjacent keratinocytes (Szabo, 1969; reviews Szabo et. al., 1988, and Ortonne, 1990). In vivo 
studies showed that exposure to UV A can also result in increased melanocyte proliferation and 
melanogenesis (DPD effect), but UV A light brought about similar biological effects to UVB light at 
UV A doses 1000 times greater than the equivalent UVB dose (Kligman et. al, 1985, Rosen et. al., 
1987). 
Little is known of the molecular mechanisms underlying the IPD and DPD effects. Several 
pathways and factors have been implicated in increasing melanogenesis and/or proliferation of 
melanocytes. The most studied consequence of UV exposure, is the enhanced melanogenic process. 
The first pathway implicated for the UV-induced melanogenesis is the diacylglycerols / protein 
kinase C pathway (DAGs / PKC) (Gordon and Gilchrest, 1989; Punnonen and Yuspa, 1992). UVB 
was shown to interact with the membrane lipids and this resulted in the release of diacylglycerols 
(DAGs, a phospholipid derived 1,2-diacylglycerol) from the membranes (Carsberg et. al., 1995; 
Friedman et. al. , 1990). This theory was supported by a study in which DAGs were applied to 
guinea pig skin resulting in a pigmentary response similar to that seen ~er UV-induced tanning 
(Allan et. al., 1995). DAGs enhanced melanin formation by increasing PKC-mediated 
phosphorylation oftyrosinase, resulting in an increase in melanin formation (Park et. al., 1993 a, b). 
A second possible pathway for UV-induced melanogenesis was suggested to be via the cGMP 
pathway. This process resulted from the release of nitrous oxide (NO), a paracrine factor released 
from the adjacent keratinocytes after the exposure to both UV A and UVB irradiation' s in vitro 
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(Romero-Graillet, 1997), and was reported to be responsible for the DVB-induced sunburn reaction 
in vivo (Warren et. al. , 1994). It was proposed that NO increased melanogenesis by mimicking the 
melanogenic effects ofUVB. This was confirmed in studies by Romero-Grailett et. al. (1996; 
1997), who demonstrated that NO donors increased the activities of both tyrosinase and TRP-1 
enzymes, and consequently melanin synthesis in melanocytes. In contrast, the melanogenic 
stimulatory effects were almost completely reversed in the presence of NO scavengers. In the same 
study, it was shown that exposure to UVB light caused a marked increase in the cGMP content in 
these melanocytes. It was also shown that inhibitors of NO synthase (the enzyme which synthesizes 
NO), guanylate cyclase and cGMP-dependent protein kinase (PKG) blocked the melanogenic 
effects ofUVB. This possibly demonstrated that the NO-cGMP pathway, through activation of 
PKG, was involved in DVB-induced melanogenesis. 
Another mechanism for UV-induced melanogenesis and melanocyte proliferation could be 
explained by the direct action of paracrine factors on melanocytes. The paracrine factor, 
endothelin-1 (ET-1 ), is known to increase both melanocytic mitogenesis and melanogenesis 
(Imokawa et. al., 1992; 1993; 1996; 1997). The increase in melanogenesis was shown to be due to 
the up-regulation of the activities and mRNA synthesis of both tyrosinase and TRP-1. An in vitro 
study by Imokawa et. al. (1997) demonstrated that these biological effects resulted from cross talk 
between the PKC, PKA and MAP kinase signal transduction pathways which was induced by ET-1 
(see Figure 1.5). Other paracrine factors, in addition, have also been shown to directly increase the 
pigmentary response of the skin. For example, nerve growth factor (NGF) released from UV-
induced keratinocytes was shown to be responsible for ensuring the survival of the melanocytes 
after UV exposure. This was due to increased levels ofBCL-2 protein, which prevented apoptosis 
of cells (Zhai et. al., 1996). 
Lastly, a mechanism by which UV light might induce melanogenesis and proliferation has been 
linked to DNA damage and/or repair mechanisms (Eller et. al., 1994; 1996, Pedeaux et. al., 1998). 
Exposure of cells to both UV A and UVB resulted in DNA damage, either by the release of ROS 
(reactive oxygen species), causing oxidative DNA damage, or by the formation of DNA photo-
adducts between the pyrimidine bases of the DNA (reviewed Applegate and Frenk, 1995; and 
Gilchrest, 1996). This damage was recognized and repaired by a nucleotide excision repair process 
(Tomaletti and Pfeiffer, 1996). The repair mechanisms involved the removal of the pyrimidine 
dimers and photoproducts induced by UV A and UVB, respectively. During this repair process, 
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integrity of the DNA. Investigators have demonstrated in cell culture experiments that the addition 
of DNA-damaging chemicals or small DNA fragments or pyrimidine dinucleotides (pTpT), which 
mimicked the fragments released during the excision/repair process, increased the melanin content 
of these cells (Eller et. al. , 1994, 1996; Pedeaux et. al., 1998). It was further shown that the DNA-
damaging chemicals and pTpT fragments increased the expression ofMSH receptors and MSH 
binding in both melanoma cells and normal human melanocytes. Thus, these DNA repair fragments 
were likely to be responsible for the observed increase in proliferation and melanogenesis after UV 
exposure, because MSH was known to increase both melanocyte proliferation and melanogenesis in 
vivo (reviewed Luger et. al., 1997). 
Several other factors are thought to play a role in the biosynthesis of melanin, but their specific 
functions have not yet been clarified. These factors include, for example, endogenous melanogenic 
inhibitors (Hatta et. al., 1988; Kameyama et. al., 1989), catalases (Halaban and Moelmann, 1990), 
peroxidases (d' Ischia et. al., 1991 , Gesualdo et. al., 1997), and agouti genes (Wilson et. al., 1995). 
1.6 VITILIGO 
Vitiligo is a depigmenting disease that affects persons of all racial groups and both sexes. It usually 
spreads from the extremities of the body, but may also commence on any part of the integument. 
The characteristic irregular milk-white spots on the exposed areas of the body tend to enlarge 
centrifugally over time. For reasons as yet unknown, lesions may spontaneously repigment in some 
patients. A trichrome pattern of colouration is relatively common in dark-complexioned patients, 
with central depigmentation, peripheral hyperpigmentation and surrounding skin of normal 
pigmentation, thus making lesions more visibly pronounced in these darker-complexioned patients 
(see Hann et. al. , 1997, for a recent review on clinical features ofvitiligo). 
1.8.1 HISTOLOGICAL CHANGES IN VITILIGO MACULES 
The question of whether lesional melanocytes die ( or merely tum-off melanogenesis) is central in 
understanding the treatment ofvitiligo. Several investigators have addressed this question 
(reviewed Le Poole and Das, 1997). The extensive immunohistochemical studies by Le Poole et. 
al. (1992; 1993; 1996) and Norris et. al. (1996) are most convincing, as they include antibodies to 
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detect melanocytes based on both pigmentary and other melanocyte-specific phenotypic 
characteristics. (This was unlike the approach used previously by other investigators, who mainly 
used antibodies that were only able to detect melanocytes actively involved in melanogenesis). The 
overall conclusions from the studies by Le Poole et. al. ( 1993, 1996), are that melanocytes are 
completely absent in long-standing / stable lesions (lesions which had not progressed in size for 
more than a year). Melanocytes, however, were found to be present in active/ progressing lesions, 
although fewer in number and seeming to have undergone degenerative changes compared with the 
melanocytes found in non-lesional skin. With the use of a confocal laser-scanning microscope, 
these degenerated melanocytes appeared to be grossly enlarged, bizarre-shaped, fragmented and 
displayed retracted dendrites. The question of whether hair-follicle melanocytes were affected at all 
in vitiligo patients was not addressed in any of these investigations. However, it has been 
mentioned in clinical reports of vitiligo patients, that the hairs found in lesional skin are usually 
pigmented, suggesting that these melanocytes of the hair follicle were somehow protected from this 
disease. 
In the study by Norris et. al. (1996), c-kit antibodies were used to detect melanocytes in punch 
biopsies from lesional, peri-lesional, non-lesional and normal skin. The findings from his study 
confirmed that c-kit protein was present on all adult melanocytes, and that the number of c-kit 
positive melanocytes in non-lesional skin was the same in normal, human control skin samples. 
Furthermore, it was shown that the melanocytes were absent in lesional skin and decreased in 
number in peri-lesional, compared to non-lesional biopsies and normal human skin biopsies. These 
c-kit results agreed with those of Le Poole et al. (1993), since staining with c-kit was only observed 
in peri-lesional vitiliginous skin and adjacent normal skin, but absent in lesional vitiliginous skin. 
In addition to the changes of the melanocytes, other cells of the vitiliginous epidermis were also 
affected. Moelmann et. al. (1982) and Bhawan et. al. (1983), demonstrated that vacuolar damage to 
the basal keratinocytes occurred in vitiligo lesions. This damage to the keratinocytes was focal and 
most extensive in areas immediately adjacent to melanocytes, which suggested that the injury to the 
keratinocytes was secondary to the release of toxic material from damaged melanocytes. On the 
other hand, damage to keratinocytes could have been caused by another factor, and these damaged 
keratinocytes could then have affected the survival of the adjacent epidermal melanocytes. In 
addition, Hann et. al. (1992), suggested that a leukocyte infiltrate, found in the epidermis of 
spreading vitiligo lesions in his study, was associated with the vacuolar changes in the basal 
keratinocytes and melanocytes. It was therefore suggested that the damage to these epidermal cells 
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was caused by the local milieu, which eventually led to the damage and ultimately, the loss of these 
melanocytes in the lesions. 
Inflammatory cells were also found to be present in vitiligo lesions. Lesions from patients with 
inflammatory vitiligo, which was recognized by the border of the depigmented macule being red 
and frequently itchy, had a higher content of inflammatory cells than that found in generalized 
vitiligo lesions (Abdel-Naser et. al., 1994; Le Poole et. al., 1996). The composition of the cell 
infiltrate consisted mainly ofT lymphocytes (Le Poole et. al., 1996), which were more numerous in 
peri-lesional skin, than in the control skin. In addition, they were mainly concentrated where 
melanocyte destruction took place and where macrophages were found (Badri et. al., 1993). 
Langerhans cells, which are one of the most important cells involved with the immunity of the skin 
(Misery et. al., 1997; 1998), were also increased in number in peri-lesional vitiligo skin, when 
compared with that in non-lesional and lesional skin. An alteration in the number of inflammatory 
cells in peri-lesional vitiligo skin, compared to the control skin, suggested that a local immune 
reaction could. be involved in the degenerative process of melanocytes in vitiligo. 
1.6.3 CAUSES OF VITILIGO 
The factors responsible for causing vitiligo should ideally be known so that they could be removed 
or inhibited during treatment. The exact aetiology of vitiligo remains unknown. This could therefore 
account for the variable results obtained with different treatment modalities. The actual cause of 
vitiligo is one of the most debated questions around this disease, and unfortunately, there is no 
plausible answer as yet. From previous studies it would seem that the mechanisms of melanocyte 
destruction are likely to be a combination of many different processes influencing melanocyte 
function and survival. Several theories have been proposed for the pathogenesis of vitiligo, but 
because it is beyond the scope of this study, a brief summary of the most prominent theories are 
described below. 
The neural theory proposes that a neural dysfunction exist in vitiligo patients. Ultrastructural 
studies of the dermal nerves from biopsies taken from marginal and central vitiliginous skin lesions, 
showed mild degenerative changes in a small proportion of the axons and Schwann cells of the 
nerves which supplied these lesions (Al' Abdie et. al., 1995). Since a communication pathway 
between the nervous system and epidermal melanocytes exists (Hara et. al., 1996), an alteration in 
the structure or function of the nerves would disturb the function of the cells they supplied. An 
alteration of nerves would possibly result in abnormal levels of neurotransmitters being released 
from the nerve-endings, which could be toxic to the melanocytes (reviewed Ortonne and Bose, 
1993). The reported abnormal levels of both catecholamines (Morrone et. al. , 1992; Chakraborty 
and Chakraborty, 1996) and acetylcholine (Elwary et. al., 1997) neurotransmitters in vitiligo 
patients, strengthens this proposal. 
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The self-destruct theory proposes that vitiligo results from the destruction of melanocytes by toxic 
products made by the melanocytes themselves (reviewed Ortonne and Bose, 1993; Pawelek et. al., 
1980). There are several variants of this hypothesis. Firstly- there is an overproduction of or an 
inability to inactivate certain enzymes and /or intermediate products of melanin synthesis, which are 
regarded to be toxic to the melanocytes, for example, hydrogen peroxide. Secondly- there are 
multiple defects in catalase (an enzyme that inactivates hydrogen peroxide) activity (Maresca et. al., 
1997; Passi et. al., 1998). This enzyme is also involved in catecholamine synthesis in the epidermis 
of vitiligo pati~nts, and therefore the abnormal catecholamine metabolites mentioned previously, 
could be explained (Morrone et. al., 1992; Schallreuter et. al., 1996). Defective catalase activity 
leads to an accumulation of hydrogen peroxide in the epidermis, which is damaging to the 
melanocytes and surrounding cells. Thirdly- melanin fails to remove toxic free radicals, the 
accumulation of which kills the cells. 
A number of observations, supporting the autoimmune theory, include the following: 
(1) The most convincing evidence that vitiligo is an autoimmune disease, was the demonstration 
that there were specific antibodies to melanocyte cell-surface antigens present in the blood 
circulation of most vitiligo patients. These antibodies were initially demonstrated by 
immunoprecipitation (Naughton et. al., 1983; Mitchell et. al., 1980) of melanocyte-surface antigens 
and by indirect immunofluorescence (Bystryn et. al., 1985). Their presence was confirmed by other 
investigators using additional techniques such as complement-dependent cytotoxicity (Norris et. al., 
1988), antibody-dependent cellular cytotoxicity (Yu et. al., 1993; Norris et. al., 1988), 
immunoblotting and by live-cell enzyme-linked immunoabsorbent assay (ELISA) and passive 
transfer experiments (Harning et. al., 1991; Gilbar et. al., 1995, Kemp et. al., 1996; 1997 a,b; 1998; 
1999; Baharav et. al., 1996). Furthermore it was reported that these antibodies correlated with the 
extent and activity of the disease, and have the ability to kill melanocytes in vitro and in vivo 
(Harning et. al., 1991; Gilbar et. al., 1995, Durham-Pierre, 1995). Moreover, it was shown that the 
titre of melanocyte antibodies decreased in vitiligo patients that responded to PUV A therapy, 
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confirming that the antibody titre was related to the disease activity (Hann et. al., 1997). 
(2) Numerous patients with vitiligo have other autoimmune diseases including diabetes mellitus and 
alopecia areata (Lerner et. al., 1978). In addition, a large proportion of patients with vitiligo 
showed a 2-10 fold increase in the auto-antibodies to numerous organs, particularly the adrenals and 
thyroid (Gokhale et. al., 1983; Mandry et. al., 1996). 
(3) Relationships between vitiligo and melanoma suggested that immune reactions targeting 
melanoma cells could also destroy normal human melanocytes (Cui and Bystryn, 1995). This was 
supported by the clinical observation that melanoma was often associated with a vitiligo-like 
depigmentation within, around, or distal to the melanoma (Bystryn et. al., 1987; Merimsky et. al. , 
1994; 1996). The up-regulation oflnterleukin-2 (IL-2) was also reported to cause vitiligo in 
patients with melanoma, but not in those with other diseases (Richards et. al., 1992). It was 
presumed that in these patients, IL-2 up-regulated preexisting immune-cell responses to pigment 
cell antigens on melanoma, resulting in the destruction of normal human melanocytes in the 
process. Support for the up-regulation ofIL-2 in vitiligo patients is provided in the recent study of 
Yeo et. al., 1999. 
The oxidative stress theory proposes that melanocyte destruction result from the depletion of anti-
oxidants or the increase in the levels of reactive oxygen species (ROS) and other free radicals 
within the melanocyte. This results in the anti-oxidant levels becoming insufficient to counteract 
these radicals. This was supported by studies that showed that both non-enzymatic anti-oxidants, 
including vitamin E, GSH (glutathione), total ubiquinone (CoQ1oH2 and CoQ10) and the enzymatic 
antioxidant, catalase (CAT), were significantly reduced in vitiligo patients compared to the levels in 
the control patients (Schallreuter et. al. , 1994 a, b; Maresca et. al., 1997; Passi et. al. , 1998). Further 
support for the destruction of melanocytes by free radicals was shown in a study by Passi et. al. 
(1998), who demonstrated that a reduction in phospholipid-polyunsaturated fatty acids occurred in 
vitiligo patients, compared to normal patients. When there is an increase in ROS in a cell, 
lipoperoxidation of cell membranes takes place, and this involves the use of phospholipid fatty 
acids. Therefore the higher the levels of ROS in the epidermis, the lower the levels of phospholipid 
fatty acids in the epidermis (reviewed Applegate and Frenk, 1995). Thus, reduced levels of 
phospholipid-polyunsaturated fatty acids ofvitiligo patients could be explained possibly by the 
increasing levels of free radicals within the epidermis of these patients. These studies thus support 
the oxidative-stress theory that suggests that the free radicals that cause damage to the melanocytes 
are the initial pathogenic event, which triggers melanocyte degeneration in vitiligo. 
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The oxidative stress theory also ties in with another theory for melanocyte destruction, which 
proposes that defective recycling of tetrahydrobiopterins in the epidermis ofvitiligo patients, 
results in the depigmentation of skin lesions. This theory is briefly explained in conjunction with 
Figure 1.6. At this stage, in my opinion, this theory appears to be the most plausible for explaining 
the pathogenesis ofvitiligo, since it attempts to account for most of the biochemical changes 
observed in vitiligo patients. Thus, all the theories mentioned above, except for the autoimmune 
theory, could possibly co-exist. This theory is based on the fact that in vitiligo patients, there is a 
decrease or an absence of the enzyme, 4a-hydroxy-B~ [-5,6,7,8-tetrahydrobiopterin] dehydratase 
(Schallreuter et. al., 1994 a, b, c). To explain how the auto-immune theory can co-exist with the 
other theories, it is in my opinion that the initial decrease of the enzyme 4a-hydroxy-B~ [-5,6, 7,8-
tetrahydrobiopterin] dehydratase results from an immune reaction which targets this pathway and 
eventually leads to an interference in the synthesis of this enzyme. Since the states of immunity for 
the various individuals will be different, the degree of interference of enzyme synthesis will also 
vary. Consequently, the degree of depigmentation and also the biochemical changes that are 
observed in the different individuals will vary. To test this theory, a study should be done to 
determine whether the patients who spontaneously repigmented, have had a boost in their immune 
systems. This can be done by comparing their T cell counts found within the depigmented areas to 
those counts found within in the area that spontaneously repigmented. Furthermore, a study should 
be carried out to compare the 7-B~ levels ofvitiligo patients, who are repigmenting 
(spontaneously or after treatment), to the levels before they had started repigmenting, in order to 
shed some light on the feasibility of this theory. 
An explanation on how the decrease in the levels of 4a-hydroxy-B~ dehydratase could possibly 
result in the skin depigmentation will now follow. The decrease in this enzyme may result in an 
accumulation of 7- B~ (7-tetrahydrobiopterin) in the epidermis, which is an inhibitor of the 
enzyme, phenylalanine hydroxy lase (P AH), which is responsible for the conversion of 
phenylalanine to tyrosine. Thus, inhibition of P AH activity, means less phenylalanine will be 
converted into tyrosine. Consequently, depigmentation will occur, since tyrosine is the starting 
material for pigment synthesis. The decrease in P AH activity in vitiligo patients was confirmed by 
the abnormally high phenylalanine levels seen in the in vivo study by Schallreuter et. al. (1998). 
Furthermore, the accumulation of7-B~ and phenylalanine, see Figure 1.6, may lead to an increase 
in the levels of hydrogen peroxide. This may possibly result in the altered catalase activity in 
vitiligo melanocytes, as demonstrated by several investigators (Schallreuter et. al., 1991; Maresca 
et. al., 1997). In addition, the accumulation of phenylalanine is said to set up a feedback 
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FIGURE 1.6 Above: Schematic diagram of the de novo biosynthesis and recycling of 6-BH4 
in regulation of L-tyrosine production by phenylalanine hydroxylase in the human 
epidermis (from Schallreuter et al., 1994a) 
Below: Schematic diagram indicating that L-tyrosine is the common substrate for melanin 
biosynthesis by melanocytes and catecholamines biosynthesis by keratinocytes (from 
Schallreuter et. al., 1994b) 
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mechanism which leads to increased levels of the biopterins (6- B&), which are converted into 7-
B&, and thus may lead to even further depigmentation. These biopterins were also shown to be 
toxic to melanocytes in vitro (Schallreuter et. al. , 1994 a, b, c). Because of the ability of these 
biopterins to fluoresce after exposure to UV A light, it is clinically possible to differentially 
diagnose vitiligo from other leucodermas. The increase in 6-BRi levels may also result in an 
increase in catecholamines synthesis in keratinocytes (see Figure 1.6), which in turn could explain 
the increased monoamine oxidase activity observed in vitiligo patients (Schallreuter et. al., 1996). 
Moreover, this theory also provides an explanation for the increased plasma and urinary levels of 
catecholamine metabolites observed in vitiligo patients (Moronne et. al., 1992; Schallreuter et. al. , 
1994c). 
1.7 VITILIGO THERAPY 
A large variety of therapeutic agents are being or have been tested for the treatment of vitiligo 
(reviewed Grimes et. al., 1993; Nordlund and Majumder et. al., 1997; Falabella et. al., 1997; 
Mandel et. al., 1997). PUV A photochemotherapy, which involves combining the drug psoralen (a 
furocoumarin) with UV A, is the treatment that currently provides the most satisfactory results for 
repigmenting the skin of vitiligo patients. PUV A photochemotherapy has been shown to increase 
the number of epidermal DOPA (L-3-4-dihydroxy-phenylalanine )-positive melanocytes, resulting 
in an increase in melanin production in vivo (Blog and Szabo, 1979; Park et. al., 1990). The exact 
mechanism by which PUV A brings about its biological effects is not known, nor is its 
pharmacological action entirely clear. 
The first clues as to how PUV A acts were deduced from the observation that peri-follicular spots, 
which were "islands" of pigment around the hair follicles, arose when patients responded to PUV A 
therapy. These spots eventually coalesced and formed larger areas of pigmentation. In contrast, 
vitiliginous skin in the non-hair bearing body regions did not repigment at all or repigmented very 
little after PUV A treatment. This suggested that PUV A treatment stimulated pigmentation of the 
depigmented skin by stimulating the migration of the melanocytes from the hair follicle. Light 
microscopic and ultrastructural studies supported this theory by demonstrating that PUV A enhanced 
the repigmentation of vitiliginous skin by stimulating the inactive melanocytes in the outer root 
sheath (ORS) of the hair follicle to divide, to proliferate and to migrate upward along the surface of 
the ORS, into the nearby depigmented epidermis (Ortonne et. al. , 1979; 1980; Cui et. al., 1991). In 
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addition, the melanocytes at the borders of vitiliginous lesions were also shown to be stimulated in 
this manner. 
In order to understand the mechanism of this peri-follicular spreading, it was proposed that the 
highly proliferative melanocytes within the ORS, which acted as a reservoir, were preferentially 
stimulated by the growth factors released from the PUV A-irradiated epidermal cells. To test this 
theory, Abdel-Nasser et. al. (1997) grew melanocytes in the sera of patients that had been irradiated 
with PUV A for several months, and as a control, grew melanocytes in the sera drawn from the same 
patient prior to PUV A irradiation. The proliferative rate of the melanocytes grown in PUV A-
irradiated sera tripled that of the melanocytes grown in non-PUV A irradiated sera. It was therefore 
proposed that PUV A acted on epidermal keratinocytes or dermal components to release melanocyte 
growth stimulatory factors into the sera of these patients, thus enhancing the proliferation and later 
the migration of melanocytes into the depigmented epidermis. 
A second proposed theory for the mechanism of action of PUV A was based on the fact that DNA 
damage enhanced melanogenesis and melanocyte proliferation, as discussed previously under 
ultraviolet light. Both, psoralen alone and the photochemical product of the combination of 
psoralen and UV A, damage DNA by intercalation with DNA bases, formation of DNA 
photoadducts or by the formation ofreactive oxygen species (Morliere et. al. , 1988; Kinley et. al., 
1994; Gasparro et. al., 1997). This damage would result in the release of fragments during the 
repair process of the cells, which possibly enhances MSH activity (Pedeaux et. al., 1998; Gasparro 
et. al., 1997). Consequently, there is an increase in the content of photo-protective eumelanins 
within the cells and also an increase in melanocyte numbers in vivo, as explained previously. 
A third theory proposed for the increase in melanocyte number and melanogenensis by PUV A also 
involves the action of MSH. Both PUV A and UVB were shown to enhance the number of 
epidermal DOPA-positive melanocytes and melanin production in vivo (Szabo et. al., 1969; 
Ortonne et. al. , 1979; 1980; Blog et. al., 1979; Kinley et. al., 1994; Gilchrest et. al., 1996). In vitro, 
however, PUV A and UVB inhibited melanocyte proliferation but enhanced melanin production 
(Kao and Yu, 1992; Abdel-Malek et. al., 1994; Mengeaud and Ortonne, 1996). An explanation for 
the growth inhibitory effects with PUV A and UVB is possibly explained by the increase in the G2 
phase of their cell cycle of cultured melanocytes exposed to UVB light (Abdel-Malek et. al., 1994). 
This is the phase during which repair of the cell takes place and the cell ' 'protective" genes, for 
example, p53 tumour-suppresser genes, may be up-regulated (Im et. al., 1998). However, in vivo, 
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this is the phase in which MSH activity is the highest, and melanocytes will probably become more 
responsive to MSH. Therefore, prolonging this phase possibly may result in pre-existing 
melanocytes to generate new functional melanocytes (increased proliferation) and an increase in 
melanin production may also occur. It can thus be predicted that iflong-term cultures of PUV A-
treated melanocytes were carried out (a study not yet done by any investigator), the initial inhibition 
of melanocyte proliferation would probably be followed by an increase in melanocyte proliferation, 
once the initial damages by PUV A and UVB were overcome. 
The fourth proposed theory for PUV A-induced melanogenesis, is the formation ofpsoralen-fatty 
acid adducts, which stimulate melanogenesis via the PKC signal transduction pathway. 
Investigators reported that PUV A photo-products intercalated with the phospholipids of the cell 
membranes and formed psoralen-fatty acid adducts (reviewed Zarebska et. al., 1994). These 
psoralen-fatty acid adducts were recently isolated by the investigators, Anthony et. al. (1997) and 
Frank et. al. (1998), and it was demonstrated that they were similar in structure to diacylglycerols 
(Caffieri et. al ,, 1996). Since DAGs are known to increase tyrosinase activity via the PKC pathway 
(Gordon and Gilchrest, 1989; Farago and Nishizuka, 1990; Park et. al. , 1993), it was suggested that 
psoralen-fatty acid adducts increased melanogenesis by mimicking DAGs and thus stimulated this 
pathway. This theory was supported in part, by the study of Frank et. al. (1994), who demonstrated 
that psoralen-fatty acid adducts increased tyrosinase activity and melanin production in cultured 
human melanocytes, whereas the fatty acids alone and the psoralen itself had no effect on 
melanogenesis. Furthermore, a recent investigation by Anthony et. al. (1997), showed that when 
8-MOP (8-methoxypsoralen)-fatty acid adducts were substituted for DAGs in a cell free system, 
there was an increase in the PKC pathway. Finally, the tumour promoting phorbol esters were 
reported to have a DAG-like structure (Castagna et. al., 1982; Nishizuka, 1984; 1988), and it was 
suggested that PUV A mimicked the action of these tumour promoters and caused an increase in 
melanocyte proliferation and melanogenesis. If PUV A carried out its mechanism along the same 
pathway whereby these phorbol esters carried out their function, both the repigmentary and 
carcinogenic reports of PUV A treatment could therefore be accounted for. 
In the last theory for PUV A-induced melanogenesis, the melanocytes are indirectly affected. This 
theory proposes that PUV A have an immunosuppressive effect on the skin, which creates a 
favorable milieu for melanocyte survival and growth. The immunosuppressive effects of PUV A 
were postulated because several investigators showed that psoralen, 8-MOP, PUV A and UV A 
decreased the proliferative rate of cells involved in the immunity of the body. For example, the rate 
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of proliferation of human T lymphocytes was demonstrated to be decreased in vitro (Badri et. al., 
1993). In addition, a decrease in CD4\ CDS\ and IL-2 receptor expressions were also reported in 
PUV A-treated vitiligo patients in vivo (Johnson et. al., 1996; Lauharantu, 1997). The decrease in 
antibody titres against melanocytes observed after PUV A therapy of vitiliginous skin also supported 
the immunosuppressive role ofPUV A (Hann et. al. , 1997). 
1.8 REASONS FOR THE SEARCH FOR AN ALTERNATIVE TREATMENT 
FOR VITILIGO 
There are numerous unwanted adverse effects of PUV A treatment (Wolff, 1990; Weinstock et. al., 
1995; Leroy et. al., 1996; Buckley and Rogers, 1996; reviewed Lauharanta et. al., 1997; Wang et. 
al. , 1997). These can be divided into short and long-term adverse effects. The short-term and most 
common adverse effects include a phototoxic, erythematous skin reaction, pruritus, nausea and 
headaches. While the short-term adverse effects are limited and reversible after discontinuation of 
treatment, potential long-term adverse effects such as accelerated skin aging, dyskeratotic skin 
conditions, melanoma and non-melanoma skin cancer, immunological alterations and cataract 
formation are of great concern. Children under 12 years of age have a greater risk of developing 
cataracts and irreversible retinal damage than older patients, since they have not yet developed 
protective chromophobes. During a typical photochemotherapy session, the patient is exposed to 
photons of ultraviolet-A light, and the chromophobes are responsible for the absorption of excessive 
photons. Thus, damage to the retina occurs if these chromophobes are decreased in number. The 
increased risk of carcinogenesis with PUV A photochemotherapy is possibly explained by the fact 
that the newly formed photochemical psoralen derivative, which intercalates with cellular DNA, 
results in errors of the DNA repair process. In addition, the immunosuppressive side effects of 
PUV A may also partly explain the tumour-promoting effect (as suggested above) ofPUV A, since 
the immune system is important for recognising and eliminating transformed cells. In addition, of 
great concern to the light-complexioned vitiligo patient, is the fact that PUV A could repigment 
adjacent normal skin as well. Therefore the contrast in colour between the normal and vitiliginous 
skin, is still visible. An alternative treatment for vitiligo is thus being sought. 
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1.9 KHELLIN AND UVA (KUVA), AS AN ALTERNATIVE TREATMENT FOR 
VITILIGO 
Khellin is a naturally occurring furochromone, which is isolated from the seeds of Ammi visnaga 
(Arabic khella), and is similar in structure to psoralens (Figure 1. 7). When khellin was combined 
with UV A, it was reported to repigment vitiligo skin as effectively as PUV A photochemotherapy 
(Abdel-Fattah et. al., 1982; Honigsman et. al., 1985; Orte! et. al., 1988; Orrechia and Perfetti, 1992), 
and without the adverse effects reported with PUV A treatment (Wolff, 1990). In contrast to PUV A, 
the occurrence of a phototoxic skin reaction with KUY A photochemotherapy, was unreported. In 
addition, KUY A formed a lower number of crosslinks with DNA compared to PUV A, and therefore 
had a lower genotoxic potential (Vedaldi et. al. , 1988; Morliere et. al., 1988; Riccio et. al., 1992). 
Furthermore, KUY A did not hyperpigment adjacent non-vitiliginous skin (Abdel-Fattah et. al. , 
1982; Honigsman et. al. , 1985, Milne et. al., 1999), as was the finding with PUV A treatment. 
However, despite the above encouraging reports with KUY A treatment, dermatologists are not 
using this drug for vitiligo, since only a few in vivo and in vitro studies have been carried out with 
this drug. 
Khellin was used extensively in the 1940-1950's as a coronary vasodilator in the treatment of 
asthma and angina pectoris, until better treatments were discovered. No long-term adverse effects 
were reported in the ten years that this drug was used for asthma and angina, except for an increase 
in liver transaminases in certain patients. Thus, a liver complication was regarded as a contra-
indication for the use ofkhellin. A possible explanation for this was, that khellin might have acted 
as an inhibitor of the microsomal cytochrome P-450 sub-enzyme of the liver, and was capable of 
inhibiting cytosolic enzymes (Schimmer and Rauch, 1998). The study by Bech-Thompsen and 
Wulf (1995), gave the first and only report of carcinogenicity with KUY A photochemotherapy in 
vivo. Tumours were formed after mice were treated with high UV A doses and 5% khellin cream, 
but no skin tumours were formed with low doses of UV A and 5% khellin cream. Since several in 
vitro results demonstrated that khellin formed cross-links with DNA in the presence of UV A, 
exposure to high UV A doses possibly resulted in tighter or more cross-links being formed, and 
therefore increased the potential for mutagenicity in these mice. In addition, UV A itself is well 
documented to be carcinogenic (Applegate and Frenk, 1995; Burren et. al., 1998), therefore the 
likelihood of high doses of UV A promoting carcinogenicity in these mice, is also probable. Despite 
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Figure 1.7: Molecular structures of KHELLIN (A, a furochromone) and 
PSORALEN (B, a furocoumarin). From Riccio et. al., 1992; Vedaldi et. 
al., 1988; modified from Kinley et. al., 1994. 
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treatment), more mice with tumours were produced with PUV A treatment in this study. This 
suggested that KUV A treatment was possibly safer and a better alternative treatment for vitiliginous 
skin than PUV A treatment. 
The molecular mechanism(s) by which KUV A repigments vitiliginous skin are not known. Most of 
the studies done thus far, have been aimed at determining whether KUV A was a better agent than 
PUV A clinically. To establish whether KUV A was less mutagenic than PUV A, the potential of 
forming crosslinks with DNA in vitro by KUV A, was compared to that of PUV A in several studies. 
The genotoxicity ofkhellin was assessed in the following studies: Morliere et. al., (1988), found 
that khellin did not induce cross-links in the DNA of yeast cells. In contrast, it was found that 
khellin was able to form a few inter-strand crosslinks in the DNA of both Ehrlich ascites cells and a 
Salmonella strain (Vedaldi et. al. , 1988; Riccio et. al. , 1992). In this latter study, the inter-strand 
crosslinks formed within the Salmonella strain, occurred at psoralen concentrations 8-fold lower 
than the khellin concentration, and the UV A dose in PUV A treatment, was 13-fold lower than that 
used with KUY A treatment. Thus the notion that khellin may be safer than psoralens for clinical 
use, was highly supported. Trabalzini et. al. (1990), on the other hand, determined whether DNA 
damage, which may lead to mutagenicity, occurred by photo-oxidation of the DNA by KUV A, 
which was seen with PUV A treatment. It was revealed that KUV A had no photo-oxidising effect 
on the DNA. This study also provided further support for KUV A being less genotoxic than PUV A, 
and possibly a better therapeutic agent than PUV A. 
There has been only one study that has provided some evidence for a possible mechanism of action 
ofkhellin and KUV A (di Stefano et. al., 1995). It was shown in the latter study that khellin alone 
and even more so KUV A, mediated its action via a receptor. In HeLa cells, it was shown that 
KUV A had an affinity for the Gi-protein-coupled pertussin-toxin sensitive protein receptors and 
also acted on adenylate cyclase. It is not known how repigmentation of the skin was brought about 
through these receptors, since no other study has investigated this finding any further. 
While the above studies suggest that KUV A is a viable alternative treatment to PUV A, not much is 
known about the mechanism of action of KUV A in repigmenting vitiliginous skin. Indeed, it is not 
even known whether KUV A has a direct effect on the pigment cells itself or indeed whether it has a 
direct effect on the melanogenic pathway of these cells at all. Thus the broad aim of this study is to 
contribute towards the understanding of the mechanism( s) by which the khellin and UV A 
combination (KUV A), repigments the skin ofvitiligo patients. The specific aim of this project was 
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to use an in vitro tissue culture system to evaluate the effects of the drug khellin, UV A and KUY A 
on melanocyte proliferation and pigmentation. The studies were carried out on cultured human 
melanoma cells, normal human melanocytes and 3T3 fibroblasts as the non-melanocytic control cell 




What is the effect of khe/lin, UVA and KUVA on the proliferation of 
melanoma cells and normal human melanocytes? 
Is the proliferative effect of khellin, UVA and KUV A pigment-cell specific? 
What is the effect of khellin, UVA and KUVA on melanogenesis? 
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CHAPTER 2 
MATERIALS AND METHODS: 
[2.1] CELL LINES/ CELL CULTURE 
2.1.1. UCT MEL-1 
This cell line was obtained from Mr. G. Hanekom (Dept. of Clinical Science and Immunology, 
UCT). It was derived from a primary malignant tumour, which was excised from a patient at 
Groote Schuur Hospital, Cape Town (Roal, E .G., Ph.D. thesis, 1981, UCT). Roal (1981) described 
Mel-I cells as displaying both dendricity and melanization throughout the passaging in vitro. The 
melanogenic state of later passages of Mel-1 cells was more recently characterized by Davids 
(Masters thesis, 1997, UCT). He demonstrated that these cells had an eumelanin content that was 
3.3 times higher than that of the 3T3 fibroblasts, and showed that the rate of melanin formation of 
Mel-1 cells was 9 times higher than that of3T3 fibroblasts. Furthermore, by means ofNorthem 
blotting and RT-PCR analyses, it was demonstrated that Mel-1 cells expressed TRP-1, TRP-2 and 
low levels oftyrosinase genes. The pigmented nature ofMel-1 cells is clearly demonstrated in 
Figure 2.1, where the colour of the cell pellets of Mel-1 cells, 3T3 fibroblasts and normal 
melanocytes is shown. This figure shows that Mel-1 cells are slightly less pigmented than the 
normal melanocytes, but clearly more pigmented than the 3T3 fibroblasts. 
Melanoma cells were grown in RPMI-1640 medium, supplemented with I 0% foetal calf serum 
(FCS) and I OOIU/ml penicillin and I OOmg/ml streptomycin. The medium was changed twice 
weekly. For all the proliferation studies, the cells were lifted with trypsin/EDTA (0.02% 
trypsin/0.05% ethylenediamine tetraacetic acid) and lxl04 cells were plated in triplicate into wells 
of microtiter dishes. Cells were counted as described in Section 2. 3. 1.1 
2.1 .2. 3T3 FIBROBLASTS 
3T3 fibroblasts were grown under standard culture conditions. The cells were cultured in RPMI-
1640 medium supplemented with I 0% FCS and 100 IU/ml penicillin and I 00 mg/ml streptomycin, 
in a 37°C humidified 5% CO2 atmosphere. Sub-confluent cell cultures were always maintained to 
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Figure 2.1: Increased pigment density of cell pellets. After 
trypsinization, each cell suspension was pelleted in a tube by centrifugation of 
2.500g for 5 minutes. The cells are represented in the photograph above as: A, 
3T3 fibroblasts; B, Mel-1 melanoma cells; C, normal melanocytes 
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prevent the formation of variants. For the proliferation studies, 5x103 cells were plated in triplicate 
into wells of microtiter dishes. 
2.1.3. NORMAL HUMAN MELANOCYTES 
Normal human melanocytes were obtained by a modified procedure previously described by 
(Balaban et. al. , 1984; Eisinger et. al. , 1982). In short, normal human melanocytes were cultured 
from neonatal and adult foreskins of routine circumcision, courtesy of Dr. Ebrahiem, a general 
surgeon at Gatesville Medical Centre (South Africa), and foreskins were also obtained from Dr. 
N.A Parker, a general practitioner. The initial cultures of normal human melanocytes were grown 
from human skin samples, which were obtained from Dr. Dommisse, a plastic surgeon at Claremont 
Hospital (South Africa). These cultures were not used for experimental work, due to the low yield 
of cells and the fact that these cells proliferated much slower than neonatal melanocytes. All the 
processing was carried out with sterile instruments and under sterile culture conditions. The skin 
samples were transported on ice in Ham's Fl O medium, supplemented with 1 % 
penicillin/streptomycin and 0.1 % Fungizone. The skin samples were washed in phosphate-buffered 
saline (PBS, pH 7.4, see appendix), were cleansed of excess subcutaneous tissue, cut into small 
pieces (5 x 5 mm) and incubated overnight at 40c in trypsin/EDTA solution [0.25% trypsin/ 0.05% 
EDTA in PBS (pH 7.4), 1% penicillin/streptomycin and 0.1% Fungizone]. The epidermis was 
teased apart from the dermis with a fine forceps, and then the dermis was discarded. The epidermal 
sheets were dissociated by manual fragmentation and then triturated in a 1 ml Gilson tip or vortexed 
into a single cell suspension as described by Eisinger et. al. (1982). The cell suspension was added 
to a petri dish and then cultured in Buffalo rat liver (BRL)-conditioned medium, (see Appendix and 
paragraph 2.1.4 for details), which was supplemented with 20% FCS, 16mM TP A, O. lmM IBMX, 
100IU/ml insulin, and 1% cholera toxin. This medium preferentially supported the growth of human 
melanocytes. The cells were left at 37°C in a 5% CO2 humidified chamber overnight and allowed 
to adhere. The following day, the medium containing dead cells and other cell debris was sucked 
off and fresh medium was added to the dishes. When contamination of fibroblasts or keratinocytes 
was suspected after visual inspection of the dishes with a phase contrast microscope, Geneticin 
(lOOµg/ml , Sigma) was added daily to the culture dish for up to seven days if necessary (Balaban 
et. al., 1984). The cells were continually cultured at 370c in a 5% CO2 atmosphere, and the 
medium was changed every alternate day for the first two weeks and twice weekly thereafter. 







































































































































































































































































































































































UV A and KUY A on normal human melanocytes. For the proliferation assays, the cells were lifted 
with trypsin/EDT A (0.02% I 0.05%) and plated in triplicate at a density of 2xl04 cells/ml into wells 
of the microtiter dishes. See Figure 2.2 (a, band c). 
2.1.4. BUFFALO RAT LIVER CELLS 
Buffalo-rat liver cells are a source of steel factor (Zsebo et. al., 1990), which is essential for the 
maintenance, survival, proliferation and differentiation of normal human melanocytes (Kunisada et. 
al., 1998). These cells were grown to confluence in Ham's Fl 0, 20% FCS and supplemented with 
1 OOIU/ml penicillin / 100 mg/ml streptomycin and 1 mM L-glutamine at 3 70c in 5% humidified 
CO2 atmosphere. The medium was changed twice a week until the dish was confluent. From then 
onwards, the medium was collected every day. This collected medium contained the steel factor 
produced by the BRL cells. BRL-conditioned medium was then filter-sterilized with a 0.45µm 
filter before supplements were added (see Appendix). 
2.1.5. HOECHST STAINING 
Before any of the experiments were commenced, cultures were tested for the presence of 
mycoplasma contamination. Mycoplasma is a type of bacteria, which is not visible 
microscopically. It has no cell wall, and since the antibiotics, penicillin and streptomycin, act by 
inhibiting cell wall synthesis (Goodman et. al., 1990), the antibiotics are thus ineffective for this 
type of infection. Because mycoplasma contain DNA, the fluorescent bisbenzimidazole dye, 
Hoechst 33342 (see Appendix), can bind to this DNA after it penetrates the plasma membrane. 
Therefore, mycoplasma-contarninated cultures could be detected under a fluorescent microscope by 
their characteristic particulate or filamentous pattern of fluorescence on the cell surface, or the 
surrounding cell cytoplasm if the contamination was heavy. Furthermore, since mycoplasm take up 
thymidine from the culture medium, infected cultures would show signs of deterioration or a 





Before the experiments described below were commenced, it was necessary to first find the most 
ideal vehicle for khellin. This very problem of finding the most appropriate vehicle for dissolving 
pigment cell modulators, was recently addressed in the paper of Virador et. al. (1999). It was found 
that khellin (Sigma) displayed poor solubility in water, PBS, absolute ethanol and 70% ethanol. 
Thus a variety of solutions were tested as vehicles for khellin (see Chapter 3, page 40, paragraph 1 
ofResults). It was concluded that DMSO (di-methylsulfonamide, BDH) was the most ideal vehicle 
for the dissolution ofkhellin. For the experiments described below, khellin was dissolved in the 
vehicle, DMSO, and was stored as a 1 OOmM sterile stock solution at 4°C, protected from light with 
foil. In addition, khellin solutions were added to the cells in a dark sterile hood. The necessary 
dilutions were made with the culture medium to obtain the appropriate khellin concentration. A 
concentration ofless than 1 % DMSO, was maintained throughout the experiments. Growth curve 
studies of Mel-I melanoma cells treated with various doses of DMSO in culture medium revealed 
that DMSO slightly inhibited the growth rate of melanoma cells. However, the results were 
expressed relat_ive to the control, which was also treated with DMSO. 
2.2.2. CULTURE PLATING PROCEDURES 
After lifting the cells from the dish, they were inoculated at a density of lx10
4 and 5x103 cells per 
well of both Mel-I and 3T3 fibroblasts, respectively. Similarly, normal human melanocytes were 
plated at a density of 2x10
4 cells per well. The cells were allowed to attach overnight to the culture 
dish in the standard culture medium. The next day, the melanocytes were exposed to the respective 
experimental treatment procedures. 3T3 fibroblasts served as a negative cell line for all 
experiments. The cells were plated in triplicate and all experiments were repeated at least thrice. 
2.2.3. EXPOSURE OF CELLS TO KHELLIN ALONE 
The medium of the cells was replaced with various concentrations of khellin. The cells were 
exposed to khellin for four days, and thereafter, assessment of results was made. All experiments 
were repeated at least thrice, and using different batches of cells if at all possible. The cells were 
exposed initially to a wide concentration range ofkhellin, and a more optimal dose range was then 
discovered. This dose range was used for the experiments that followed. 
J 
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were repeated at least thrice, and using different batches of cells if at all possible. The cells were 
exposed initially to a wide concentration range ofkhellin, and a more optimal dose range was then 
discovered. This dose range was used for the experiments that followed. 
2.2.4. EXPOSURE OF CELLS TO UVA ALONE 
Two days after plating, melanoma cells were exposed to UV A light with doses ranging from O -
480mJ/cm2. An optimal proliferative UV A dose was then discovered and used for all subsequent 
experiments. Exposing cells to UV A light involved the following: 
(i) Exposure to UV A light took place in a customized UV A cabinet, fitted with UV A lamps 
(wavelength of365nm). The energy was measured with a Waldmann Lichttechnik 
radiometer, intensity of 0.8mW/ cm2. The doses of UV A were determined by using the 
following formula: Dose (mJ/cm2) = radiometer reading (mW/cm2) x time in seconds. A 
standard curve was used to determine the time of UV A exposure for a particular dose to be 
delivered to the cells experimentally. 
(ii) The cells were plated into the dish, which was placed at a standard 30cm distance from the 
UV A source for all the UV A experiments. 
(iii) To exclude any UVB rays, a 4mm plate glass was placed over the lid of the dish, which 
served as a UVB filter. In addition, the customized UV A cabinet was painted black to 
prevent reflection of UV A rays, which could affect the actual UV A dose delivered to the 
cells. 
(iv) The dish with cells was placed in an ice bucket to prevent detachment of cells due to the 
heat energy released during the irradiation procedures. 
(v) Medium was aspirated from the dishes before the irradiation procedure, in order to avoid the 
formation of medium-derived toxic photo-products, which could be induced after UV 
exposure (Kao and Yu, 1992), and were irradiated in the presence of PBS. 
(vi) 48 hours after seeding of the cells, the cells were exposed to 30mJ/cm2 - 480mJ/cm2 of UV A 
light. 
(vii) Immediately after irradiation, PBS was aspirated and replaced with the standard culture 
medium. The dish was then placed at 37°C, in a humidified 5% CO2 atmosphere for four 
days. The medium was changed every two days. 
(viii) The control cells were covered with a black cloth for the entire irradiation procedure within 
the UV A cabinet ( called sham-irradiation). 
2.2.5. EXPOSURE OF CELLS TO KUVA (KHELLIN COMBINED WITH UVA) TREATMENT 
The same precautions as mentioned in sections 2.2.3 and 2.2.4 were followed during the KUY A 
treatment protocol. 
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One day after seeding the cells and one day before the phototreatment, normal medium was 
replaced with medium containing 0.0lmM, 0.1mm and lmM khellin, and the cells were incubated 
overnight. The next day, medium was replaced with pre-warmed PBS and exposed to a single dose 
of250mJ/cm2 UV A light. The sham-irradiated cells, treated with or without khellin, were covered 
with a black cloth and were also present in the UV A irradiation cabinet during the irradiation 
procedure. Immediately after irradiation, the PBS was replaced with basal medium containing 
O.OlmM, 0. lmM and lmM khellin into the appropriate wells. Responses were measured after a 
further four days of cell culturing in the presence ofkhellin, and medium was changed every two 
days. 
2.2.6. . ASSESSMENT OF RESULTS 
Four days after the experimental exposure of cells, the results were assessed by the method 
described below under the sections: proliferative assay, melanin formation assay and western 
blotting. 
[2.3] ASSAY PROCEDURES 
2.3.1. Cell Proliferation Assay 
Initial attempts were made to measure proliferation with 3H-thymidine incorporation (see 
Appendix) and a XTT cell proliferation kit (Boeringer Mannheim). However, the small quantities 
and slow growth rate of the normal human melanocyte cultures, rendered these methods unsuitable. 
Therefore, cell proliferation was assessed by counting. 
2.3 .1.1. Cell Counting Protocol 
After the cells in the microtiter dishes were treated with khellin, UV A or KUY A, the medium was 
aspirated, and the cells were washed twice with 300µ1 PBS (pH 7.4). The cells were removed from 
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the dish, after the addition of 50µ1 of trypsin/EDT A at room temperature to each well (2 - 4 
minutes). 150 µI of medium supplemented with FCS was added to inactivate the enzyme. The cells 
were triturated with a Gilson tip set at 200µ1, before being placed into Eppendorf tubes, which were 
centrifuged at 2,500 g for 10 minutes at room temperature in a bench top centrifuge. 150µ1 of the 
supernatant was removed and the pellets were re-suspended in the rest of the supernatant (50µ1). 
The cell suspension was then vortexed for 5 seconds, followed by cell counting, using a 
haemacytometer. Each experiment was performed in triplicate, and the entire experiment was 
repeated at least thrice. The initial experiments were done in conjunction with the trypan-blue 
exclusion dye assay. The result recorded is a reflection of only viable cell numbers counted. 
[2.3 .2] Cytotoxic Assay 
Cells were incubated in the presence ofkhellin (0-lmM) alone, as described above (2.2.3) for four 
days. Trypan-blue exclusion dye assay was used to count both the viable and non-viable ( dead) 
cells. The results are recorded as the number of viable cells, which is expressed as a percentage of 
the total number of cells (number of both viable and dead cells) in the culture dish of the 
experiment. The lower the percentage of viable cells for example, the higher the percentage of dead 
cells. This experiment was only done once and was carried out in duplicate. 
[2.4] PROTEIN DETERMINATION 
Protein assays were carried out using either the BCA (bicinchoninic acid assay, Pierce) assay kit or 
the Bio-rad protein assay. (See appendix) 
[2.5] IN VITRO RADIOMETRIC ASSAYS 
2.5.1. MELANIN FORMATION ASSAY: 
The melanin formation assay measures the incorporation of 14C-tyrosine into acid insoluble 
melanin, and gives a measure of the melanocyte-specific enzyme activities of the entire melanin-
forming pathway (Hearing and Ekel, 1976). The cells were exposed to khellin alone, UV A alone 
and KUV A as described earlier, before melanin formation assays were carried out. The protein 
concentrations of the cell lysates used in these assays were·-standardised to the lowest protein 
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concentration, before each assay (see Appendix) was performed. Each assay solution (final volume 
25 µI) contained: 
1 Oµl enzyme preparation or 1 Oµl O. lM phosphate buffer only ( control sample), 5µ1 L-(U-14C)-
tyrosine {25(Ci/ml, specific activity 513mCi/mmol., The Radiochemical Centre, Amersham}, 
a 5µ1 of a solution containing lmg/ml chloramphenicol, lmg/ml cycloheximide, lOOOIU/ml 
penicillin-G and O. lmg/ml bovine serum albumin, and 5µ13 ,4-dihydroxy-L-phenylalanine 
(0.05mM in O. IM PBS (pH 7.4). 
The assay samples were incubated in triplicate for three-and a half-hours at 3 7°C. 20µ1 of each 
sample was pipetted onto GF/C glass microfibre filter discs. The discs were then treated as follows: 
three washes with 150ml ice-cold 10% TCA (Trichloroacetic acid, see Appendix), one 5 minute 
wash with 96% (Iv) ethanol, and one 5 minute wash in acetone which removed unwanted cellular 
debris from the discs. This was followed by transfer of the filters to scintillation vials, and air-
drying for I hour at room temperature or 30 minutes at 37°C. The precipitated proteins on the 
filters were then solubilised by the addition of 200µ1 Soluene-350 (Packard) onto the filters, and the 
vials were incubated at 37°C for I hour. This was followed by the addition of 7µ1 of glacial acetic 
acid to neutralise the Soluene-350, to reduce chemiluminescence during scintillation counting 
(Zinsser Analytic, Germany, manufacturer's instructions, personal communication). Finally, 10ml 
Quicksafe scintillation fluid (Packard) was added to each vial, and ten minute counts were 
performed in a Beckmann liquid scintillation counter. The controls used were blanks from which 
the enzyme was omitted. Each assay was expressed as percentage cprn/µg of protein and as a 
percentage of the experimental untreated control. 
(2.6] WESTERN BLOTTING 
After the cultured cells were exposed to KUV A, the cells were harvested and solubilized overnight 
at 4°C in CEB (see Appendix), then centrifuged at 12000g for 15 min at 4°C, and the supematants 
were then recovered. Protein concentrations were determined with the BCA assay (Pierce) and Bio-
rad assay (Bio-rad laboratories) kits, and bovine serum albumin was used as the standard. Equal 
amounts of protein (40µg) were loaded in each lane of a 7.5% SDS poly-acrylamide gel, and 
electrophoresed under reducing conditions, after which proteins were transferred onto Hybond ECL 
nitrocellulose membranes (Amersham). Following blocking for 4 hours at room temperature (RT) 
in 10% non-fat dry milk powder in TBS/Tween (0.1% Tween-20 in Tris buffered saline), the blots 
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were incubated with the following rabbit antisera, which were obtained as gifts from Dr Vincent 
Hearing, National Cancer Institute): a- PEP8, a polyclonal antibody against the carboxy terminus of 
mouse TRP-2, 1:500 dilution in 5% milk powder in TBS-T; a-PEP?, a polyconal antibody against 
the carboxy terminus of tyrosinase; 1: 500 dilution in 5% milk powder in TBS-T, overnight at room 
temperature. The membranes were then washed twice with TBS-T for 20 minutes and incubated 
with horseradish peroxidase-conjugated swine-anti-rabbit lgG secondary antibody (1: 1500 dilution 
in TBS-T) for 30 minutes at RT. After washing the membranes four times with TBS-T, the 
immunoreactive proteins were detected by Enhanced Chemiluminescence (Amersham), according 
to the manufacturer's instructions: 
(2.7] STATISTICAL ANALYSIS 
The analyzed results were a reflection of at least triplicate samples, unless otherwise indicated, from 
various groups of experiments. The data of the results were represented as the mean+/- S.E.M. in 
the whole study. To determine the significance of the results, a Student t-test was performed 
between group comparisons. A 95% confidence interval was set and therefore, p < 0.05, was 
considered statistically significant. 
(2.8] CALCULATION OF POPULATION DOUBLING (From Celis, 1991) 
The population doubling of a culture was calculated directly from the cell count numbers. The 
increase in population doublings was calculated by the following formula: NH/ N 1= 2\ where NH= 
the number of cells harvested after treatment and N1= the number of cells inoculated, and X= the 
number of population doublings. Another way to present this calculation is as follows: 







In order to cany out studies on the effect of khellin on melanocyte proliferation and melanogenesis, 
it was first essential to establish the best way to dissolve the drug in the tissue culture medium. 
Previous investigators have used a variety of vehicles for dissolving khellin, including, absolute 
ethanol (Kinley et. al., 1994; di Stefano et. al. , 1988), Tris buffer pH 7.4 (Morliere et. al., 1988) and 
other aqueous solutions (Vedaldi et. al. , 1988), for in vitro studies. In addition, oil-in-water 
emulsions (aqueous cream, Honigsman et. al., 1985, Milne et. al., 1999), acetone and propylene 
glycol (Orrechia et. al., 1992), were used in vivo. In the present study water, PBS, absolute ethanol, 
70% ethanol and DMSO were tested as possible vehicles. It was found that DMSO was the only 
vehicle that dissolved the drug effectively. To determine whether DMSO would affect the 
proliferation of Mel-I cells and 3T3 fibroblasts, the cells were exposed to a range ofDMSO 
concentrations. It was found that DMSO was cytotoxic to both Mel-I cells and 3T3 fibroblasts, 
especially at concentrations above 1 % v/v. Thus, for all the experiments that followed, DMSO was 
used at a maximum concentration of 1 % v/v. 
All experiments were repeated at least three times, except where otherwise indicated. 
Khellin stimulates the proliferation of human melanoma cells and normal human melanocytes 
(NHMs), but inhibits the proliferation of fibroblasts. 
To determine whether khellin stimulates cell proliferation, assays were carried out on Mel-I 
melanoma cells and 3T3 fibroblasts exposed to khellin for 4 days over a concentration range from 
lnM (10-9 M) to lmM (10-3 M). As seen in Figure 3.1, khellin stimulated proliferation of Mel-I 
cells over a broad range ofkhellin concentrations, from 1nm to O. lmM, with maximal stimulation at 
O.Ol mM (10-5 M). At this maximal dose, after four days, the total number of cells in the dishes was 
increased 2.35-fold above the untreated control. In contrast to the results of the Mel-I melanoma 
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FIGURE 3.1: Effect ofKhellin (lnM-lmM) on Proliferation ofMel-1 Melanoma cells and 3T3 
Fibroblasts. Growth profiles of Mel-I melanoma cells (orange line) and 3T3 mouse fibroblasts 
(purple line) cultured in khellin medium for four days. The data depicted in this figure are 




cells, exposure of 3T3 fibroblasts to khellin resulted in a decrease of the total number of cells in the 
dishes, over the entire concentration range tested ( 1 nM-1 mM) (Figure 3. 1). 
To obtain a better understanding of the kinetics ofkhellin enhanced proliferation ofMel-1 
melanoma cells, time course assays over a four day period were carried out (Figure 3 .2). The 
results revealed that even at day 1, khellin was stimulatory at doses below O.SmM. At day 4, an 
even more pronounced stimulatory proliferative effect was obtained at doses below O.SmM. 
Maximum proliferation was observed with 0.0lmM khellin, which confirmed previous 
observations. At this dose, a 2.1-fold increase in the growth rate of Mel-1 cells was obtained, after 
four days of treatment. 
In all the above experiments, the numbers of cells per dish were reduced when they were treated 
with khellin at concentrations of 0.SmM and above. This suggested that these higher doses of 
khellin had a cytotoxic effect on the melanoma cells. To test this hypothesis, cytotoxic assays with 
trypan-blue dye exclusion were carried out on melanoma cells treated with O.OlmM, O. lmM and 
lmM khellin (see Figures 3.3 [a] and [b]). The results from these assays suggest that lmM khellin 
is indeed cytotoxic and not merely cytostatic to the melanoma cells (see Figure 3.3a). Thus, for 
example, at day four, only 28% of Mel-I cells were able to exclude trypan blue (remained viable) 
compared to the control dish, wherein 100% of the cells were viable. Addition ofO.OlmM and 
O. lmM khellin, in contrast, resulted in more than 98% of the melanoma cells remaining viable. 
These results clearly demonstrate that the higher doses ofkhellin are cytotoxic and that lower doses 
are not cytotoxic and stimulate proliferation of melanoma cells. 
The effect ofkhellin on the proliferation of 3T3 fibroblasts was also determined in this study 
(Figure 3.4). It was found that khellin reduced the total number of 3T3 fibroblasts per dish. This 
reduction was seen over the entire concentration range tested. To determine whether this decrease 
in cell numbers was due to the cytotoxicity of the drug, cytotoxic assays were also carried out on 
3T3 fibroblasts that were treated for four days with khellin (0-lmM). The results revealed that only 
22% of the fibroblasts were able to exclude trypan blue after four days of treatment with lmM 
khellin (Figure 3.3b). These results suggest that at lmM, khellin is cytotoxic to the fibroblasts. 
Furthermore, the results indicate that lmM khellin is as cytotoxic to the fibroblasts as it is to the 
melanoma cells. Analysis of the effect oflower doses ofkhellin on fibroblasts revealed a slightly 
different picture compared to the melanoma cells. These results suggested that O. lmM khellin was 
more cytotoxic to the fibroblasts than the melanoma cells. Interestingly, O.OlmM khellin did not 
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Figure 3.2: Effect ofKhellin (O.OlmM- lmM) on Proliferation ofMel-1 Melanoma 
cells. Growth profile ofMel-1 melanoma cells grown in the presence ofkhellin, with 
different colours representing the various concentrations, over a time course period of four 
days. Control cells were grown in RPMI 1640 medium with 1% DMSO and with no 
khellin. Data are presented as the mean cell number ± S.E.M. of at least 6 separate 
experiments, and each performed in triplicate. 
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Figure 3.3 a, b: Percentage Viable Mel-1 cells (A) and 3T3 Fibroblasts (B) treated 
with Khellin (0 - lmM). Cells were cultured in the absence ofkhellin (blue diamonds) or in the 
presence ofO.OlmM (purple squares), O. lmM (yellow triangles) or lmM (light blue asterisks) khellin 
for four days. The data are representative of one experiment, which was performed in duplicate. 
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Figure 3.4: Effect of Khellin (O.OlmM - lmM) on Proliferation of 3T3 
Fibroblasts. Growth profile of 3T3 mouse fibroblasts grown in the presence of 
khellin, with different colours representing the various concentrations, over a tine 
course period of four days. Control cells were grown in RPMI 1640 medium with 
I% DMSO and with no khellin. Data are presented as the mean cell number ± 










appear to be significantly cytotoxic to the fibroblasts, even though a decrease in the cell numbers of 
fibroblasts was observed in the cell proliferation assays (Figure 3.4). These results suggest that at 
the lower doses ofkhellin, the drug is cytostatic, whereas the higher doses ofkhellin, is cytotoxic to 
the fibroblasts. Doses higher than lmM khellin were not tested in this study. 
Establishment of normal human melanocyte cultures 
In order to investigate the effect of khellin on normal human melanocytes (NHMs ), it was necessary 
to establish cultures of melanocytes from skin biopsies. Cultured melanocytes were derived from 
foreskins of circumcised infants of different races. Most times, melanocytes from different racial 
groups were cultured together and then used for experiments. Though this was clearly not ideal, it 
was necessary to do this in order to obtain large numbers of melanocytes that were needed for the 
experiments. In the present study, NHMs were found to have a decrease in their proliferation rate 
after about 4-5 weeks in culture. Thus, cultures of about two weeks old were always used to ensure 
that cells were proliferative when treated. 
Because of the difficulties in obtaining large quantities ofNHMs and the scarcity of material, 
studies on cultured normal human melanocytes were carried out only at concentrations ofkhellin 
that were shown to have maximal stimulatory effect (O.OlmM and 0. lmM khellin) and cytotoxic 
effect ( I mM) on Mel- I melanoma cells. In dishes treated with O. 0 I mM and O .1 mM khellin, the 
total number of cells increased by 1.8-fold and 1.4-fold, respectively (Figure 3.5). T-tests revealed 
that the differences were significant at the p < 0.05 level, compared to the untreated control cells. 
Although it was not shown in this figure, khellin also inhibited the proliferation of the fibroblasts, as 
previously reported (Figures 3.1, 3.4). 
UV A stimulates the proliferation of human Mel-1 melanoma cells, but had no effect on the 
proliferation of normal human melanocytes and fibroblasts. 
To determine the effect of UV A on proliferation, Mel-I cells and 3T3 fibroblasts were exposed to a 
single dose of UV A irradiation, in the dose range of30 - 480mJ/cm2, as described in Materials and 
Methods (Figure 3.6). After exposure to UV A doses ofless than 150mJ/cm2, no significant 
difference in the proliferation of the Mel-1 cells, compared to the sham-irradiated ( control) cells, 
was seen. However, proliferation was enhanced at doses between 150-280mJ/cm2 UV A, with a 
maximal stimulation at 250mJ/cm2. At this maximal dose, proliferation was increased by 2.1-fold 
above the sham-irradiated control cells. For all subsequent experiments, a UV A dose of250mJ/cm2 
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Figure 3.5: Effect of Khellin (O.OlmM - lmM) on Proliferation of Normal Human 
Melanocytes. Growth profiles of normal human melanocytes treated with khellin over a 
four-day time course period. The control cells were cultured only with medium and 1 % 
DMSO. The data represented is the mean number of cells ± S.E.M of at least 4 separate 
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Figure 3.6: Effect of UV A on Proliferation of Mel-1 Melanoma cells and 3T3 
Fibroblasts. Growth profiles of Mel-I human melanoma cells (pink line) and 3T3 
mouse fibroblasts (blue line), exposed to a single pulse of UV A light and then 
cultured for four days. The data depicted in this figure are presented as the mean 
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was always used. When fibroblasts were exposed to the same range of UV A doses as the 
melanoma cells, proliferation was unaffected. 
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When the effect of UV A on the proliferation ofNHMs was determined, only single dose 
experiments (using the optimal dose established for melanoma cells) were carried out (Figure 3.7). 
This was mainly due to the limited number of cells available for these experiments. In this study, a 
single dose of250mJ/cm2 UV A light had no effect on the proliferation ofNHMs, compared to the 
sham-irradiated cells. However, in this figure it seemed as if UV A light had inhibited the 
proliferation ofNHMs, but the t-test results revealed that differences were not significant at the p 
<O. 05 level, compared to the sham-irradiated control cells. This suggested that under the conditions 
of this experiment, UV A did not stimulate the proliferation of NHMs. These results were later 
confirmed by the results obtained in Figure 3.9. As before, the proliferation of3T3 fibroblasts was 
not affected by UV A light. 
Khellin and UVA (KUVA) treatment stimulates the proliferation ofMel-1 melanoma cells and 
NHMs, but inhibits the prolif era ti on of fibroblasts. 
The above results demonstrate that khellin alone and a single dose of UV A alone are able to 
stimulate the proliferation of melanoma cells. In NHMs, khellin alone but not UV A alone had a 
stimulatory proliferative effect. In order to determine the combined effect of these two treatments, 
cells were cultured overnight in O.OlmM or O. lmM khellin, and then exposed to a single dose of 
250mJ/cm2 UV A. Following UV A exposure, the cells were cultured in khellin medium for a further 
four days. Results are presented in Figures 3.8, 3.9 and 3.10. In figures 3.8 and 3.10, a solid line 
represents the khellin and UV A combination (KUV A), while the dotted line represents the cells 
treated with khellin alone (unirradiated). The colour of each line represents a particular dose of 
khellin to which the cells were exposed. 
The results clearly demonstrate that khellin plus UV A (KUV A) stimulates proliferation of 
melanoma cells more effectively than either khellin or UV A alone (Figure 3. 8). Thus, for example, 
after four days in culture, O.OlmM khellin plus 250mJ/cm2UV A (pink solid line) stimulated the 
proliferation 2.9-fold above the untreated controls (black dotted line), as compared to the 1.6-fold 
stimulation with 0.0lmM khellin alone (pink dotted line) and the 1.2-fold stimulation with UV A 
alone (black solid line). This pattern of results was clearly visible even after the first day of KUV A 
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Figure 3.7: Effect of UV A on Proliferation of Normal Human Melanocytes (A) and 3T3 
Motnse Fibroblasts (B). Growth profiles of normal human melanocytes (white columns) and 
3T3 mouse fibroblasts (black columns) exposed to a single pulse of UV A light and cultured for 
four days. The sham-irradiated ( control) cells were covered with black paper and exposed to the 
same experimental conditions as the irradiated cells. The data represented in this figure is the 
mean number of cells± S.E.M of at least 5 separate experiments, each petformed in triplicate. 
* P > 0.05 (result insignificant), versus sham-irradiated cells. 
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Figure 3.8: Effect of KUV A on Proliferation of Mel-1 Melanoma cells. Growth profile of 
Mel-I melanoma cells grown in the presence of khellin and UV A (KUV A) over a four-day time 
period. Treatment of cells with the combination ofkhellin, O.OlmM (pink line) and O. lmM (green 
line), and UV A is represented by a solid line, and without UV A (khellin alone), by a dotted line. 
The overall control is represented by a dotted black line (khellin and UV A absent). Data are 
represented as the mean cell number± S.E.M. of at least 5 separate experiments, each performed 
in triplicate. 
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compared to the 1.3-fold stimulation with O.lmM khellin alone (green dotted line) and the 1.2-fold 
stimulation with UV A alone (black solid line). 
In order to determine whether the combination of O.01 mM khellin and UV A was acting additively 
or synergistically, the effect of individual and combined treatments on the population doublings was 
calculated, as described in Materials and Methods (Section 2.8). After four days, the untreated cells 
had undergone approximately 1.5 population doublings, whereas the cells treated with O.OlmM 
KUV A had undergone approximately 2.97 population doublings. Thus, the combined treatment 
(KUV A) increased the proliferation rate by 2. 97-1 . 5 = 1. 4 7 population doublings in 4 days, which is 
an increase of98% (1.47 /1.5 x 100= 98%). In the same time period, cells treated with khellin 
alone, had undergone 2.1 population doublings. When compared to no treatment at all, this 
constituted an increase of 0.6 (2.1-1.5= 0.6) population doublings or 40% (0.6 I 1.5 x 100 = 400/o). 
Treatment with UV A alone, however, resulted in 1.68 population doublings. This constituted an 
increase of 0.18 population doublings or an increase of 12% (0.18 / 1.5 x 100 = 12%). If the effects 
were additive,. one would thus have expected an increase in the proliferation rate of 40% + 12% = 
52% or less. However, both treatments combined led to almost double this increase in proliferation 
rate, namely 98%. This clearly indicates that the combination ofkhellin and UV A act 
synergistically to stimulate proliferation. 
In order to determine whether the combination ofO. lmM khellin and UV A was acting additively or 
synergistically on the proliferation rate of the melanoma cells, the calculation as described above 
was also carried out. After four days of treatment, the untreated cells had undergone approximately 
1.5 population doublings, whereas the cells treated with KUV A had undergone approximately 2.2 
population doublings. Thus, the O. lmM KUV A combination increased the proliferation rate by 2.2-
1.5 = 0. 7 population doublings in 4 days, which is an increase of 47%. In the same time period, 
cells treated with O. lmM khellin alone had undergone 1.73 population doublings, which constituted 
an increase of0.23 population doublings or an increase of 15.3%, when compared to no treatment at 
all. Treatment with UV A alone, however, resulted in 1.68 population doublings, which constituted 
an increase of0.18 population doublings or an increase of 12%. If the effects were additive, one 
would thus have expected an increase in the proliferation rate of 15.3% + 12% = 27.3% or less. 
However, both treatments combined led to almost double this increase in proliferation rate, namely 
47%. This also clearly indicates that the combination ofO. lmM khellin and UV A act 
synergistically to stimulate proliferation. 
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In this study, it was also determined whether the proliferation rate ofNHMs would be affected by 
the combined treatment of 0.0lmM khellin and UV A (see Figure 3.9). The results revealed that the 
O.O l mM KUV A combination stimulated the proliferation of these cells by 2-fold, in comparison to 
the 1.6-fold increase with O.OlmM khellin alone. UV A alone had no effect on the proliferation of 
NHMs, which confirmed previous findings. T -tests of NHMs treated with O.01 mM khellin and 
UV A (KUV A), revealed that the differences were significant at the p < 0.05 level, compared to the 
untreated control cells (untreated with both khellin and UV A). 
As described for the melanoma cells, calculations were then carried out to determine whether the 
combination of O.OlmM khellin and UV A was acting additively or synergistically on the treated 
NHMs. These calculations may possibly be inaccurate due to the fact that an estimate of the 
starting cell number had to be made. It was estimated that after four days of treatment with 
O.Ol mM KUV A, the cells had undergone 1.3 population doublings. Without any treatment, these 
cells had undergone 0.33 population doublings within the same time period. Thus, KUV A 
treatment increased the proliferation rate by 1.3-0.33= 0.97 population doubling in 4 days or 294% 
(0.97 I 0.33 x 100= 294%). In the same time period, cells treated with khellin alone had undergone 
1 population doubling. When compared to no treatment at all, this constituted an increase of0.67 
(1-0.33= 0.67) population doublings or 203% (0.67 I 0.33 x 100 = 203%). Treatment with UV A 
alone, however, resulted in no increase in population doublings, compared to the untreated controls. 
If the effects of khellin and UV A were additive, one would thus have expected an increase in the 
proliferation rate of203% + 00/o = 203% or less. However, both treatments combined led to an 
increase in the proliferation rate of 294%. This clearly indicates that the combination ofkhellin and 
UV A results in a synergistic proliferative effect. 
It was then calculated whether the combination of O .1 mM khellin and UV A was acting additively or 
synergistically on the proliferation rate of NHMs. After four days, the cells treated with KUV A had 
undergone 1 population doubling. Thus, the O. lmM KUV A combination increased the proliferation 
rate by 1-0.33 = 0.67 population doublings in 4 days, which is an increase of203%. In the same 
time period, cells treated with O. lmM khellin alone had undergone 0.8 population doublings, which 
constituted an increase of0.5 population doublings or an increase of 167%, when compared to no 
treatment at all. Treatment with UV A alone, however, resulted in no increase in population 
doublings, compared to the untreated cells. If the effects were additive, one would thus have 
expected an increase in the proliferation rate of 167% + 0% = 167% or less. However, both 
treatments combined led to an increase in the proliferation rate that was much more than this, 
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Figure 3.9: Effect ofKUVA on Proliferation of Normal Human Melanocytes. Growth 
profiles of normal human melanocytes treated with khellin and UV A (KUV A). Treatment with 
khellin alone is represented by the single tone columns, 0.0lmM (red columns) and 0. lmM 
(green columns), and dual-tone columns represent the combination ofkhellin and UV A 
(KUVA) treatments. The overall control (black column) of the study was only treated with 
medium and I% DMSO. The cells treated with UV A alone are represented by the black dual-
tone column. The data represented in this figure is the mean number of cells ± S.E.M of at least 
3 separate experiments, each performed in triplicate. * P < 0.05 (significant) and **P < 0.01 
(result extremely significant), versus control. 
namely 203%. This provides proof that the combination of O. lmM khellin and UV A act 
synergistically to stimulate proliferation. 
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The effect ofKUV A on 3T3 fibroblasts was also investigated, and the results shown in Figure 3.10, 
revealed that the proliferation of 3T3 fibroblasts was decreased with KUV A combination 
treatments. This growth inhibition was observed to be inversely proportional to the khellin doses. 
A very interesting finding was that the KUV A treatment was more cytotoxic to the fibroblasts than 
the treatment with khellin alone, at all concentrations. 
In conclusion, KUV A combination treatments more effectively enhanced proliferation of melanoma 
cells and NHMs than khellin or UV A alone. The O.OlmM KUV A combination stimulated 
proliferation of both melanocytes and melanoma cells maximally. The proliferation of3T3 
fibroblasts was inhibited with all the KUV A combination treatments tested, and these were more 
cytotoxic than khellin or UV A alone. 
Khellin, UV A and KUV A treatments enhance melanogenesis in human melanoma cells and 
NHMs. 
To determine the effects ofkhellin alone, UV A alone and KUV A, on melanogenesis in Mel-1 cells 
and NHMs, the cells were treated as described for the proliferation assays, and their ability to 
synthesize melanin was measured using a standard radiometric assay. The results are presented as a 
percentage of the control activity. The percentage increase was obtained by subtracting the 
percentage control value from the percentage experimental value. For the assays with khellin alone, 
the cells were exposed to O.OlmM and O. lmM khellin for four days as previously described. The 
protein was then harvested, and this was followed by the protein extracts being assayed. The results 
demonstrated that O.OlmM and O. lmM khellin enhanced melanin formation in melanoma cells by 
160% and 100%, respectively (Figure 3 .11 ). T-tests revealed that the differences were significant at 
the p < 0.05 level, compared to the untreated control cells. 
To determine the effect of UV A on the melanogenic activity of the melanoma cells, they were 
exposed to a single dose of250mJ/cm2 UV A light, cultured for four days and then the protein 
harvested for assaying. This treatment enhanced the melanogenic activity of Mel-1 melanoma cells 
by 30% above the sham-irradiated control cells (Figure 3.12). T-tests revealed that the differences 
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Figure 3.10: Effect ofKUVA on Proliferation of 3T3 Fibroblasts. Growth profile of3T3 
mouse fibroblasts grown in the presence of khellin and UV A (KUV A) over a four-day time period. 
Treatment of cells with the combination ofkhellin, O.OlmM (pink line) and O. lmM (green line), 
and UV A is represented by a solid line, and without UV A (khellin alone), by a dotted line. The 
overall control is represented by a dotted black line (khellin and UV A absent). Data are 
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Figure 3.11 14C-Tyrosine Assay results ofMel-1 Melanoma cells and 3T3 
Fibroblasts treated with Khellin. Human melanoma cells (white columns) and 3T3 
mouse fibroblasts (black columns) were exposed to khellin for four days before 
protein was collected . Control cells were treated with medium alone and 1 % 
DMSO. The data depicted in this figure are presented as the average percentage 
cpm/µg ± S.E.M. of at least 7 separate experiments, each performed in triplicate. 
The results are expressed as a percentage of the untreated control Mel-1 melanoma 
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Figure 3.12 14C-Tyrosine Assay results of Mel-1 Melanoma cells and 3T3 Fibroblasts 
exposed to UVA light. Human Mel-1 melanoma cells (white columns) and 3T3 mouse 
fibroblasts (black columns) were exposed to a single dose of 250mJ/cm2 UV A and cultured 
for four days before protein was collected . Control cells were covered with black paper in 
the UV cabinet. The data depicted in this figure are presented as the average percentage 
cpm/µg ± S.E.M. of at least 8 separate experiments, each performed in triplicate, as 
described in Materials and Methods. The results are expressed as a percentage of the 
unexposed control Mel-1 melanoma cells.* P < 0.05 (significant), versus sham-irradiated 
control 
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To determine the effect of combined KUV A treatments, the cells were cultured overnight in 
O.OlmM and O. lmM khellin, exposed to a single dose of250mJ/cm2 UV A the following day, and 
then cultured for another four days in khellin before the protein was harvested for the assay. The 
results clearly demonstrated that khellin plus UV A (KUV A) stimulated the melanin formation of 
Mel-1 melanoma cells more effectively than either khellin, or UV A alone (Figure 3.13). Thus, for 
example, after four days in culture, O.OlmM khellin plus 250mJ/cm2 UV A increased the melanin 
formation of melanoma cells by 200% above the untreated control cells, whereas the melanin 
formation was increased 100% by O.OlmM khellin alone and 30% by UV A alone. These results 
suggest that khellin in the presence of UV A, has a synergistic melanogenic effect on the melanoma 
cells in culture. This is because, if the effects ofkhellin and UV A were additive, one would thus 
have expected a 130% (100% + 30%= 1300/o) or less increase in the melanogenic activity of these 
cells. However, a 200% increase in the melanogenic activity of these cells had resulted, suggesting 
that the melanogenic effect of the combination ofkhellin and UV A is synergistic. With the O. lmM 
KUV A combination, the melanogenic activity of these cells was increased by 130%, compared to 
the 80% increase with O. lmM khellin alone and the 30% increase with UV A alone. This also 
clearly demonstrates that the O. lmM KUV A combination treatment of melanoma cells increase 
their melanogenic activity synergistically. T-tests confirmed that the melanogenic assay results of 
Mel-1 cells treated with O.OlmM khellin and UV A, were significantly different at the p < 0.05 
level, compared to the untreated control cells. 
Like the melanoma cells, the melanogenesis of NHMs was increased in melanocytes treated with 
khellin alone (Figure 3.14). Exposure ofNHMs to both O.OlmM and O. lmM khellin increased the 
melanogenic activity of these cells by 154% and 100%, respectively. When the NHMs were 
exposed to a single dose of250 mJ/cm2UV A, the melanin formation rate was increased 30% above 
the sham-irradiated cells (Figure 3 .15). T-tests revealed significant differences in the results that 
were obtained with O.OlmM khellin alone and UV A alone, at the p < 0.05 level, compared to the 
untreated control cells (Figures 3 .14 and 3 .15). 
It was then determined whether the KUV A combination treatment had stimulated the 
melanogenesis in NHMs (Figure 3.16). The results revealed that after four days of treatment, 
O.Ol mM khellin plus 250mJ/cm2 UV A increased the melanin formation ofNHMs by 290% above 
the untreated control cells, compared to the 130% increase with O.OlmM khellin alone and the 30% 
increase with UV A alone. These results suggest that khellin in the presence of UV A, has a 
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Figure 3.13: 14C-Tyrosine assay results of Mel-1 Melanoma cells and 3T3 Fibroblasts 
treated with KUV A (khellin and UV A). Treatment with khellin alone is represented by the 
single tone columns, O.OlmM (red columns) and O. lmM (green columns), and dual-tone 
columns represent the combination ofkhellin and UV A (KUV A) treatments. The overall 
control (black column) of the study was only treated with medium and 1% DMSO. Cells 
exposed to UV A alone are represented by the black dual-tone column. The data represented in 
this figure is the average percentage cpm/µg ± S.E.M. of at least 8 separate experiments, each 
performed in triplicate. The results are expressed as a percentage of the unexposed control Mel-
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Figure 3.14 14C-Tyrosine Assay results of Normal Human Melanocytes and 3T3 
Fibroblasts treated with Khellin. Normal melanocytes (white columns) and 3T3 mouse 
fibroblasts (black columns) were exposed to khellin for four days before protein was 
collected. Control cells were treated with medium alone and 1% DMSO. The data depicted 
in this figure are presented as the average percentage cpm/µg ± S.E.M. of at least 4 separate 
experiments, each performed in triplicate. The results are expressed as a percentage of the 
untreated control normal human melanocytes. * P < 0.05 (result significant), versus control 
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Figure 3.15 14C-Tyrosine Assay results of Normal Human Melanocytes and 3T3 
Fibroblasts exposed to UV A light. Normal melanocytes (white columns) and 3T3 mouse 
fibroblasts (black columns) were exposed to a single dose of250mJ/cm2 UV A and cultured for 
four four days before protein was collected . Control cells were covered with black paper in 
the UV cabinet. The data depicted in this figure are presented as the average percentage 
cpm/µg ± S.E.M. of at least 8 separate experiments, each performed in triplicate. The results 
are expressed as a percentage of the unexposed control normal melanocytes. * P < 0.05 (result 
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Figure 3.16: 14C-Tyrosine assay results of Normal Human Melanocytes and 3T3 Fibroblasts 
treated with KUV A (kbellin and UV A). Treatment with khellin alone is represented by the single 
tone columns, O.OlmM (red columns) and O. lmM (green columns}, and dual-tone columns 
represent the combination ofkhellin and UV A (KUV A) treatments. The overall control (black 
column) of the study was only treated with medium and 1% DMSO. Cells exposed to UV A alone 
are represented by the black dual-tone column. The data represented in this figure is the average 
percentage cpm/µg ± S.E.M. of at least 3 separate experiments, each performed in triplicate. The 
results are expressed as a percentage of the unexposed control normal melanocytes. * P < 0.05 
(result significant}, versus control. 
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UV A were additive, one would thus have expected an increase of 160% (130% + 30%= 160%) or 
less in the melanogenic activity of these cells. However, a 290% increase in the melanogenic 
activity of these cells had resulted, suggesting that the melanogenic effect of the combination of 
khellin and UV A is actually synergistic. Similarly, it was shown that the O. lmM KUV A 
combination treatment enhanced melanin formation synergistically, since this treatment increased 
melanin formation by 110%, whereas both 0. lmM khellin alone and UV A alone increased melanin 
formation by 30% each. T-tests revealed significant differences in the results that were obtained 
with O.OlmM khellin plus UV A at the p < 0.05 level, compared to the untreated control cells. 
As expected, treatment of3T3 fibroblasts with khellin alone, UV A alone and KUV A had no effect 
on the melanin formation, compared to the untreated cells (Figures 3 .14, 3 .15 and 3 .16). The low 
level of 14C-tyrosine incorporation seen in the 3T3 fibroblasts represents background values. 
In conclusion, these results clearly indicate that khellin and even more so KUV A, enhances the 
melanogenic activity of both NHMs and Mel-I melanoma cells in vitro. Interestingly, these results 
also suggest that the maximal proliferative dose ofkhellin is also the maximal melanogenic dose. 
Levels of melanogenic enzymes increased in KUV A-treated Mel-1 melanoma cells and NHMs. 
To determine whether the increase in melanogenic activity in KUV A-treated melanocytic cells was 
due to an increase in the levels of melanogenic enzymes, western blot analyses of the KUV A-
treated cells (melanoma and normal human melanocytes) and their controls were carried out. The 
cells were exposed to khellin and UV A as described earlier. The antibodies used in this study 
included a-PEP-8, (a rabbit polyclonal antibody against the carboxy terminus of mouse 
dopachrome tautomerase, TRP-2), a-PEP-7 (a rabbit polyclonal antibody against the carboxy 
terminus of mouse tyrosinase) and TMH-1 ( a rat monoclonal antibody which recognizes mouse 
TRP-1). All of these antibodies cross-react with human antigens, with lower affinity than to murine 
antigens (V. Hearing, personal communication). For each western blot experiment, B16 mouse 
melanoma protein extract was included as the positive control and protein extract from 3 T3 
fibroblasts was included as a negative control. 
Immunoblotting analyses of TRP 2 protein of melanoma cells treated with khellin alone or in 
combination with UV A were first carried out. The results revealed the presence of two bands of 
about 67kDa and 75kDa (see arrows, Figure 3.17) in all the lanes, including the positive control 
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Figure 3.17: Western immunoblot analysis of levels of TRP-2 (a-PEP 8) melanogenic 
protein of MEL-1 MELANOMA CELLS treated with KUV A, khellin alone and UV A 
alone. The cells were solubilized in lysis buffer and 40µg protein from each extract was 
separated on a 7.5% SDS gel. After electrotransfer to nitrocellulose membranes, the 
blots were probed with antisera specific to TRP-2 (a-PEP-8), and the bands visualized by 
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cells (lane 7). In each lane, the bands consistently appeared as a doublet in repeat assays. In 
contrast, western blots of normal human melanocytes with a.-PEP 8 (a.-TRP 2) consistently 
revealed two single bands (see Figure 3.18). The appearance of doublets in melanoma cells is 
possibly due to alterations, mutations or alternative splicing of the melanogenic enzymes in this cell 
line. It is assumed that the upper doublet or band is the glycosylated form ofTRP 2 and the lower 
doublet or band is the non-glycosylated form. A faint non-glycosylated band was present in the cell 
extract of 3T3 fibroblasts (lane 8). This was possibly due to either a non-specific cross-reaction to 
the antibody, or alternatively it represented the TRP-2 expression by fibroblasts (as reported by 
Tachibana et. al., 1996,). 
As seen in Figure 3.17, the highest level ofTRP-2 protein was observed in the lanes of the 
melanoma cell extracts treated with KUV A, as compared to the controls, which were untreated 
(lane 2) or treated with khellin alone (lanes 4 and 6). The band present in cells treated with the 
0.0lmM KUV A combination was the most intense on the blot. It was also found that in all samples 
treated with UV A (lanes 1, 3, 5) an increase in the glycosylated form of the TRP-2 protein was 
obtained. In addition, in the presence of UV A, both O.OlmM and O. lmM khellin increased de novo 
synthesis of the TRP-2 melanogenic protein. When comparing the bands of the untreated cells to 
that treated with khellin alone, it would seem that khellin alone had no effect on glycosylation of 
TRP-2. 
As with melanoma cells, immunoblotting analyses of KUV A-treated NHMs revealed both 
glycosylated and non-glycosylated forms ofTRP-2 in all the lanes of the melanocytes and in the 
B 16 melanoma control (Figure 3 .18). It was also found that KUV A treatments resulted in an 
increase in the glycosylated form ofTRP-2, with the O.OlmM KUV A combination being the most 
effective. In comparison to the control cells, khellin alone (0.0lmM and O. lmM) had no effect, and 
a marginal increase in the glycosylated form of the protein was obtained with UV A alone. As seen 
before, the fibroblasts displayed a faint non-glycosylated band on the blots. 
Despite numerous attempts, tyrosinase could not be detected in the Mel- I melanoma cells. This 
suggests that this melanoma cell line as with many others, contain very low levels of tyrosinase. 
Tyrosinase was however, detected in NHMs and it was visible as two bands of about 65kDa and 
70kDa (see arrows, Figure 3.19). The upper band represents the glycosylated form and the faint 
lower band represented the de novo form of the protein. Examination of this figure revealed that the 
glycosylated form was more prevalent in the KUV A-treated samples than the de novo form of the 
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Figure 3.18: Western immunoblot analysis of levels of TRP-2 (a-PEP 8) melanogenic 
protein of NORMAL HUMAN MELANOCYTES treated with KUV A, khellin alone and 
UV A alone. The cells were solubilized in lysis buffer and 40µg protein from each extract 
was separated on a 7.5% SDS gel. After electrotransfer to nitrocellulose membranes, the 
blots were probed with antisera specific to TRP-2 (a-PEP-8), and the bands visualized by 
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Figure 3.19: Western immunoblot analysis of levels ofTYROSINASE (a-PEP7) 
melanogenic protein of NORMAL HUMAN MELANOCYTES treated with KUVA, 
khellin alone and UV A alone. The cells were solubilized in lysis buff er and 40µ.g protein 
from each extract was separated on a 7 .5% SDS gel. After electrotransf er to nitrocellulose 
membranes, the blots were probed with antisera specific to tyrosinase (a-PEP-7), and the 
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protein. The glycosylated form was more prevalent in all UV A-treated samples. Since khellin 
alone had no effect on tyrosinase protein levels, and the band intensities of the KUV A-treated 
samples were not any different from the samples treated with UV A alone, no absolute conclusions 
could be made about the tyrosinase protein levels in the KUV A-treated melanocytes. 
In this study, immunodetection of the TRP-1 melanogenic protein in both untreated and KUV A-
treated melanoma cells and NHMs was also carried out. Despite numerous attempts and procedural 
modifications, this protein could not be detected in both the Mel-1 melanoma cells and B 16 
melanoma controls. The inability to immunodetect TRP-1 was unlikely to be due to the cell 
extracts not expressing this enzyme, but more likely to be a technical problem. 
In summary, TRP-2 protein levels were increased most evidently in cultured melanoma cells and 
normal human melanocytes treated with both khellin and UV A. It was found that the O.OlmM 
KUV A combination was the most effective treatment in increasing TRP-2 protein levels. KUV A 
treatment of the melanoma cells increased both glycosylation and de novo synthesis of the TRP-2 
protein, whereas in NHMs, an increase in glycosylation of the protein was only obtained. However, 
khellin alone had no effect on the TRP-2 protein levels in both cultured melanocytes and melanoma 
cells, whereas UV A alone had marginally increased the levels in these cells. The western blot result 
of tyrosinase protein levels in KUV A-treated melanocytes was not entirely clear. Since these 
antibodies are more appropriate for use on mouse samples, as they are targeted to recognize the 
mouse gene products rather than the human gene products, a reduction in sensitivity of detection 
may have occurred. Thus the conclusion was drawn that no tyrosinase was detectable in the 
melanoma cells. However, from these results, it would appear that UV A was responsible for the 
increase in glycosylation oftyrosinase in the KUV A-treated melanocytes. It should be noted that 





KUV A photochemotherapy seems to be a promising new treatment for repigmenting vitiliginous 
skin. KUV A is reported to be as effective as PUV A photochemotherapy in stimulating 
repigmentation, but without its side effects (Abdel-Fattah, 1982; Honigsman et. al., 1985; Ortel et. 
al. , 1988; Orrechia and Perfetti, 1992), although the efficacy ofkhellin remains in dispute 
(Honigsman et. al., 1985; Ortel et. al., 1988; Procaccini et. al. , 1995; Milne et. al., 1999, manuscript 
submitted). The mechanism by which khellin stimulates repigmentation is not yet known, nor is it 
known whether khellin acts directly on the melanocytes, nor whether it acts in combination with 
surrounding tissues and cells. What is of particular concern, is the fact that this drug is being used 
in clinical trials (Milne et. al., 1999), even though it is not known whether khellin has a cytotoxic 
dose range at all. If a cytotoxic dose is delivered to the skin cells during treatment, an accelerated 
loss of the already scarce melanocytes in the skin and hair of vitiligo patients may occur, resulting 
in even further skin depigmentation. 
This study was carried out in order to shed some light on the mechanism of KUV A 
photochemotherapy. The main aim of this study was to use a cell biological system to investigate 
whether melanocytic cells are directly affected by treatment with khellin alone and in combination 
with UV A (KUV A). This involved determining if these treatments affected the processes of 
proliferation and melanogenesis of melanoma cells and normal human melanocytes. 
Khellin and KUVA stimulate proliferation of melanocytes and melanoma cells 
To determine whether khellin has a direct effect on the proliferation of melanocytic and non-
melanocytic cells in culture, the present study was initiated by carrying out dose-concentration 
analyses of four-day cultures of melanoma cells treated with khellin. The results demonstrated that 
khellin stimulated the proliferation of melanoma cells over a wide concentration range, with a 
maximal stimulation at 0.0lmM. Similar results were obtained with cultures ofNHMs. Khellin 
inhibited the proliferation of fibroblasts at all concentrations tested. Treatment with UV A alone 
stimulated the proliferation of melanoma cells, but not NHMs. This is similar to the results of Kao 
and Yu, (1992), though different doses of UV A were used. 
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The most significant finding of the proliferation studies was that lower doses ofkhellin (O.OlmM) 
combined with a single dose (250mJ/cm2) UV A resulted in a synergistic stimulation of melanocyte 
and melanoma cell proliferation. These results provide strong support for the clinical studies, which 
indicate that KUV A treatment stimulates melanocyte proliferation, and further indicate that KUV A 
acts directly on the melanocytes to bring about this effect. This does not exclude the possibility that 
KUV A might also be acting in a paracrine fashion in vivo. These results also clearly underline the 
importance of combining khellin with UV A (KUV A) as a novel therapy for the effective treatment 
of vitiligo. 
How does khellin and KUVA stimulate melanocyte proliferation? 
There are a number of possible mechanisms whereby khellin and KUV A could stimulate 
melanocyte proliferation. The first possibility is that khellin alone, UV A alone, or the 
photochemically modified form ofkhellin, interact with cell membrane lipids and cause the release 
of diacylglycerols (DAGs). Previous investigators have reported that in the presence of UV A light, 
psoralen, which is structurally similar to khellin, interacts with membrane lipids to form psoralen-
fatty acid adducts (reviewed Zarebska et. al., 1994; Anthony et. al., 1997; Frank et. al. , 1998), 
which are reported to be structurally similar to DAGs (Frank et. al., 1994; Caffieri et. al., 1996; 
Anthony et. al., 1997). Since tumour-promoter esters such as TPA, are reported to have a DAG-like 
structure (Castagna et. al., 1982; Nishizuka, 1984; 1988), it is therefore possible that KUV A 
increases melanocytic cell proliferation by mimicking the action of these tumour promoters. 
A second explanation for the increase in melanocyte proliferation (and melanogenesis) with KUV A 
photochemotherapy is that KUV A possibly mimics the down-stream events of ET-1 signalling (See 
Figure 1.5). ET-1 has been shown by others to stimulate both melanocyte proliferation and 
melanogenesis concomitantly, by activating the PKC, PKA and MAP kinase signal transduction 
pathways (Yada et. al., 1991; Imokawa et. al., 1996; 1997). Supporting this theory was the study 
that showed PKA-elevating agents such as cAMP increase both melanocyte proliferation and 
melanogenesis (Bertolotto et. al. , 1997). In addition, activation of the PKC pathway initiates a 
cascade of events that lead to the phosphorylation of a pivotal protein kinase, MAP kinase, which in 
turn phosphorylates and activates nuclear transcription factors, which are involved in both 
proliferation and melanogenesis of the cell. Furthermore, Shoji et. al. (1998), demonstrated that 
melanocytes were five times more responsive to PKC-activating agents than the non-melanocytic 
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keratinocytes. Therefore, ifKUV A is a PKC-activating agent, it would explain why the 
melanocytes in this study are more responsive to KUV A treatment than the non-melanocytic 
fibroblasts. Moreover, a study by di Stefano et. al. (1996), provided evidence that khellin initiates a 
cascade of intracellular responses by interacting with a pertussis toxin-sensitive Gi receptor protein. 
The ET-1 receptor is a Gi coupled receptor (Imokawa et. al., 1997, Figure 1.5). It is therefore 
possible that khellin and KUV A act via the same receptor and along the same signal transduction 
pathway that ET-1 acts, and that this is responsible for the repigmentation of vitiligo skin. 
A third possible explanation for the increase in cell number is that KUV A-induced cell stress (such 
as DNA crosslinking or photo-adduct formation) may lead to the activation of transcription factors 
involved in the processes of proliferation such as AP-1 (activational protein-I , Gasparro et. al., 
1997). Previous investigators have shown that khellin alone and even more so KUV A formed DNA 
crosslinks in vitro (V edaldi et. al., 1988; Morliere et. al., 1988; Riccio et. al., 1992). This may thus 
result in DNA damage or cell stress. Gasparro et. al. (1997) suggest that during the repair of the 
cell, DNA becomes unwound in order to restore the correct nucleotide sequence, and cellular 
transcription factors could then gain access to sites previously occluded by the native chromosome 
structure. Thus, transcription factors involved in the proliferation process could then possibly gain 
access to the nuclear area of the cell . 
The last possible explanation for the increase in cell numbers after khellin or KUV A treatment is 
that a prolongation of the G2 phase of the cell cycle might have occurred. Prolongation of the G2 
phase of the cell cycle is known to be a generalized cellular response to injury (Bolognia et. al., 
1994). Cellular injury may have occurred when DNA crosslinks are formed within the cells treated 
with khellin or KUV A. The G2 phase is the phase during which MSH is most active and this may 
result, in an increase in cell proliferation (and melanogenesis) in melanoma cells and normal human 
melanocytes (Hedley et. al. , 1998). However, in the present study, the culture medium was not 
supplemented with MSH, suggesting either that the hypothesis is not valid or some other 
mechanism is also operational. To test this hypothesis one could culture cells in the presence or 
absence of KUV A and test their responsiveness to MSH. Another possibility is that one could 
measure whether cells increase their number ofMSH receptors in response to KUV A treatment. 
Why do normal melanocytes and melanoma cells respond to UVA light differently? 
In the present study, the NHMs were not stimulated to proliferate in the presence of UV A light, 
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whereas melanoma cells did. At present, there is no agreement about how UV A light affects the 
proliferation of cultured melanocytic cells, because of different results obtained by different groups 
(Willis et. al., 1972; Blog et. al., 1979; Kilgman and Kligman, 1985; Rosen et. al., 1987; Ortonne, 
1990; Kao and Yu, 1992; Mengeaud and Ortonne, 1996). It is likely that the differences in the 
results are due to differences in experimental designs (single versus multiple exposures), culture 
conditions, different UV A doses or spectral outputs of the light sources used. One possibility not 
considered by others is that the different responses relate to different levels of melanization. The 
Mel-1 melanoma cells are less pigmented and have lower levels of melanogenic activity as 
demonstrated by the lower incorporation values of the melanoma cells in the melanin formation 
assays (see Appendix, and also see Figure 2.1 ). It is known that the higher levels of melanin in 
normal human melanocytes protect the cells from DNA damage by quenching free radicals 
(Kobayashi et. al., 1993; Memoli et. al. , 1997; Im et. al., 1998). The consequence of this is that 
there would be less DNA damage in the pigmented melanocytes and therefore critical cellular 
processes of the cells, such as proliferation, would not be stimulated. This proposal seems plausible 
since UV A light is said to bring about its biological effects by causing oxidative DNA damage by 
the release of reactive oxygen species (ROS) (Applegate and Frenk, 1995; Gilchrest et. al., 1996). 
Thus, the melanin present in the NHMs may protect the cells against damage to the DNA or cell 
membranes, and lower the chance of biological processes of the cell being disrupted. 
Another possible explanation for the failure to observe enhanced proliferation of normal human 
melanocytes in the presence of UV A is that the melanocytes are slow growing and under the 
conditions of the present experiments, small differences in proliferation might not have been 
detected. Future studies could include longer culture periods together with multiple UV A 
treatments. 
Cytotoxicity of khellin 
In the present study, it was found that khellin was cytotoxic to both melanocytic cells (melanoma 
cells and normal human melanocytes) and non-melanocytic cells (fibroblasts) at concentrations 
above 0.5mM. The degree of cytotoxicty was found to rise with increasing concentrations of 
khellin. The cytotoxic assays revealed that lmM khellin was equally cytotoxic to both melanoma 
cells and fibroblasts. It is likely that the cytotoxicity is due to the formation of DNA crosslinks, 
which leads to DNA damage, failure to repair and ultimately cell death. 
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The results of the present study also indicate that at certain concentrations (10-9 -104 M) khellin 
stimulates the proliferation of the melanocytes, but inhibits fibroblast proliferation. Trypan-blue 
dye exclusion assays suggest that at lower concentrations the khellin is merely cytostatic, as there is 
little evidence of cell death at these concentrations. Furthermore, it was found that the KUV A 
combination treatments were more cytotoxic to the fibroblasts than khellin alone. This suggests 
that a new photochemical product is possibly formed when khellin and UV A are combined. This 
suggestion awaits formal testing. 
It is not clear why KUV A treatments are more toxic to fibroblasts than melanocytes. It is possible 
that fibroblasts are more sensitive to DNA-damaging agents than the melanocytic cells, because 
melanin and its intermediate products protect the pigmented melanocytic cells from damage by 
scavenging free radicals (Schmitz et. al., 1995; Memoli et. al., 1997; Prota, 1997). Damage may 
result from KUV A-induced DNA crosslinks and from the free radicals produced during UV A 
exposure, as described earlier. Because fibroblasts do not contain melanin, they would be more 
sensitive to lower doses ofKUV A treatment. Alternatively, it is possible that the difference in the 
proliferative response of fibroblasts and melanocytic cells is due to a limitation imposed by the 
experimental design: Within the four days of analysis, the faster-growing fibroblasts would have 
undergone more population doublings than the slower-growing melanoma cells. Therefore, the 
effect ofkhellin on the proliferation might have been more evident because one is in fact evaluating 
a larger number of cells (i.e. measuring the effect on increased population doublings). For both 
melanoma cells and fibroblasts to have undergone equivalent population doublings, longer-term 
cultures of melanoma cells would be needed. To test this theory, long-term cultures or the use of 
cell lines with similar growth rates should be included in future experimental protocols. 
The fibroblast cell line used in the study was an immortal murine cell line, and the results may have 
been different if a human fibroblast cell line was used. It is possible that this mouse cell line is 
more sensitive to damage by this drug than its human counterpart. An explanation for the failure of 
mouse fibroblasts to proliferate in response to khellin is possibly because in murine cells, no or 
markedly low rates of excision repair mechanisms take place after DNA damage (Vijg et. al., 1984; 
Applegate and Ley, 1996; Rosenstein and Rosenstein, 1992), as compared to human cells. Because 
of the absence of excision repair mechanisms in the fibroblasts, the damage to the cells is not 
removed and therefore growth inhibition possibly occurs. Alternatively, lack of repair in the cells 
may possibly result in the tumour-suppressor genes, for example p53, being up-regulated and thus 
preventing the cells from dividing, as was shown by Maltzman et. al. (1984). 
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The effect of PUVA versus KUVA on melanocyte proliferation in vitro 
When the results of the present study were compared to equivalent studies on the effect of PUV A 
on the proliferation of melanocytes (Kao and Yu, 1992; Mengeaud and Ortonne, 1996; Luftl et. al. , 
1998), it was found that the KUV A results were different to those obtained with PUV A. It was 
found that whereas KUV A stimulated proliferation, PUV A inhibited proliferation. The likely 
explanation for the inhibition of the proliferation rate of cultured melanocytic cells with PUV A is 
that it is that PUV A is known to be more genotoxic than KUV A in vitro, because khellin forms 
fewer DNA crosslinks than psoralen in vitro. Since DNA crosslinking is likely to inhibit DNA 
replication, it is possible that PUV A is more growth inhibitory than KUV A. It is important to note 
that in the proliferation study with PUV A of Kao and Yu, (1992), high concentrations ofpsoralen 
was used and it is quite possible that at lower concentrations the drug would not have been as 
inhibitory. The results of the present study thus demonstrate the importance of testing drugs over a 
wide range of concentrations. 
Khellin and UVA act synergistically to stimulate melanogenesis in melanocytes and 
melanoma cells 
The results of the present study show that UV A alone and khellin alone stimulate melanogenesis in 
NHMs and melanoma cells. Significantly, the results further show that when added together there 
is a synergistic increase in melanogenesis. This synergism is most evident when the melanocytic 
cells are treated with O.OlmM khellin plus a single dose of250mJ/cm2 UV A. At this dosage, 
melanogenesis was increased by 200% and 290% in melanoma cells and NHMs respectively. 
Multiple doses of UV A were not tested in this study. 
In order to explore the molecular mechanisms by which khellin and UV A bring about this 
synergistic response, the first question was to determine whether the response was due to an 
increase in the synthesis of melanocyte-specific enzymes or a post-translational activation of these 
enzymes. If the response was due to new enzyme synthesis, one might expect to detect an increase 
in the total amount of protein in khellin and KUV A treated cells. However, the results of the 
western blots do not support this theory and there was little or no significant increase in the total 
amount oftyrosinase or TRP-2 in khellin- and KUV A-treated cells. These results strongly suggest 
that under the conditions of these experiments, khellin and even more so KUV A, bring about an 
increase in melanogenesis by post-translational enzyme activation or by the inactivation and/or 
removal of some melanogenic inhibitor (Kameyama, 1993, see Figure 4 .1) 
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There are a number of theories that could be put forward to explain these results. As described in 
the Introduction, UV light and psoralens have been shown to interact with membrane lipids, 
resulting in the release of DAG-like molecules. Based on the similar structure of psoralens and 
khellin, it is possible that khellin acts in the same way as psoralens and that it is functioning along 
the ET-1 signalling pathway. DAGs are known to activate PKC, and PKC-~ in tum has been 
shown to activate tyrosinase directly by phosphorylating serine residues in the cytoplasmic domain 
of this protein (Park et. al., 1999). This mechanism of action could explain the increase in 
tyrosinase activity observed in the present study. These results are further supported by studies 
which show that tyrosinase activity is increased by phorbol esters, which are also known to mimic 
DAG-like action (Castagna et al., 1982; Nishizuka, 1984; 1988). 
The synergistic action ofkhellin and UV A remains to be explained. It is possible that UV A causes 
a photo-modification of the khellin, making khellin a more effective stimulator of the PKC 
pathway. To test this theory, a number of experiments could be proposed. Firstly, one could test 
whether khellin treatment does indeed stimulate the release ofDAGs and in addition, one could test 
whether khellin and KUV A result in an increase in the phosphorylation of tyrosinase as described 
by Park et. al. (1999). 
An interesting observation from the present study was that UV A appeared to stimulate the 
glycosylation oftyrosinase and TRP-2 (see Figures 3.20 and 3.18). Since the glycosylated form is 
the catalytic (or most active) form of the enzyme in vivo, it seems reasonable to suggest that an 
increase in this form would result in an increase in melanogenesis. This could contribute to the 
synergism observed after UV A and khellin treatment. Interestingly, western blot results from a 
study on the effect of psoralen and UV A on melanogenesis in human melanocytes and melanoma 
cells showed a similar increase in glycosylation in the presence of UV A (Mengeaud and Ortonne, 
















































































































































































































































The long-term effect of khellin and KUVA on melanogenesis 
The above discussion has attempted to explain the increase in melanogenesis observed in 
melanocytes treated for a period of four days with khellin or KUV A. It is also possible that long-
term multiple treatments, as would be needed in clinical treatments, would bring about an additional 
response, similar to the response observed after multiple treatments of melanocytes with UV A 
during PUV A photochemotherapy (Blog et. al. , 1979; Kinley et. al., 1994; Mengeaud and Ortonne, 
1996). It is possible that the excision repair mechanism is activated in KUV A-treated cells, and this 
brings about an enhanced SOS protective response as described for UVB-induced cell damage 
(Eller et. al., 1994; 1996; Pedeaux et. al., 1998). The activation of p53 tumour-suppressor genes 
brought about by this response, could in turn directly activate the tyrosinase gene, since tyrosinase 
promoters contain p53 response elements (see review Ferguson and Kidson, 1997). A further 
alternative is that via cross-talk between the PKC and PKA pathways, Mi is activated (Bertoloto et. 
al. , 1998), and this in tum results in an increase in tyrosinase gene expression. The slight increase 
in de novo forms oftyrosinase and TRP-2 in the western blots ofkhellin and KUV A treated cells in 
the present study provide support for this theory. Further support comes from preliminary studies 
of northern blots of RNA from khellin and KUV A-treated cells, which show a slight increase in Mi 
and TRP-1 mRNA after four days of treatment (Ntusi and Kidson, pers. comm.). 
Model for the action of KUVA 
The data from the present study allows the following model to be proposed for the mechanism of 
repigmentation by KUV A. Any successful treatment for vitiligo, must firstly ensure that the 
depigmented skin lesion is repopulated with melanocytes, which are then stimulated to produce 
pigment. Transfer of pigment into the surrounding keratinocytes would ensure that skin colour is 
then restored. With this in mind, the following is proposed: 
Stage I: 
StageII: 
Both khellin and UV A could initiate the repigmentation process by triggering and 
stimulating the quiescent hair follicle melanocytes and peri-follicular melanocytes to 
re-enter the cell cycle and begin to proliferate. 
Melanocytes start to migrate into melanocyte-free areas and start to synthesize 
melanin. Melanin synthesis is stimulated in the short-term by post-translational 
activation oftyrosinase and possibly, in the long-term, by increased levels of 
Stageill: 
Stage IV: 
glycosylated tyrosinase and tyrosinase-related enzymes, and/or by the removal of 
melanogenic inhibitory substances. 
In the melanocytes, the level of melanogenesis is increased and the melanocytes 
begin to transfer melanin to the adjacent epidermal keratinocytes. Continuous 
treatment with khellin and UV A ensures that melanin synthesis in the migrating 
melanocytes continues. 
Skin colour of vitiligo lesions is restored. 
Clinical Implications 
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An important issue that is brought to light by the present study is the importance of optimizing the 
topical formulation of khellin. In the clinical trials that were carried out to evaluate the efficacy of 
the use ofkhellin by the dermatologists, Honigsman et. al. (1985) and Milne et. al. (1999, 
manuscript submitted), made up in an aqueous cream base at a concentration of 5% (200mM). 
Formulation ofthis khellin cream simply involved mixing the khellin flakes with this aqueous 
vehicle. A possible criticism of this procedure is that khellin is insoluble in aqueous vehicles, as 
demonstrated in this study, and thus, the actual concentration delivered to the skin is not known. 
Furthermore, the concentration of the drug actually delivered to the melanocytes is unknown since 
nothing is known about the trans-epidermal delivery kinetics ofkhellin. Nevertheless, it is of 
importance to note that the topical formulation (200mM) is 20, 000-fold more concentrated than the 
optimal dose for melanocytes demonstrated in the present study. This clearly highlights the 
importance of optimizing the topical formulation ofkhellin and of carrying out drug trials where 
both the dose applied and the dose delivered are accurately known. With a better cream 
formulation, the optimal dose could be delivered to the melanocytes and a better repigmenting 
response might be expected with fewer side effects. In addition, from an economic point of view, if 
lower quantities ofkhellin are used in the new cream formulation, it will mean that costs to the 
patient and the Health Department will be much less. All of these factors should lead to better 
patient compliance. This is a particularly important consideration in a country like South Africa 
where many poor patients have to travel long distances for treatment at tertiary hospitals by 
specialists. Since khellin is safe to use with the natural sunlight that is so abundant in South Africa, 
these poorer patients will benefit tremendously from an effective treatment that can be used as a 
home-based treatment, as reported in the study by Milne et al. (1999; manuscript submitted). 
Related to the issue of solubility is the question of cytotoxicity. The higher the solubility ofkhellin 
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in a vehicle, the higher the dose ofkhellin that will be delivered to its target cells. The cytotoxicity 
of khellin at higher doses demonstrated in this study provides an explanation for the ineffectiveness 
of the topical application ofkhellin used in a study by Procaccini et. al. (1995), as a treatment for 
vitiligo. In this study, patients applied khellin on one side of their body either as a 5% cream in an 
aqueous base or as a 3% cream in l-methyl-2-pyrrolidinone (PYR), a drug-enhancing vehicle for 
the dissolution ofkhellin. On the opposite side of the body, the vehicles were applied as the control 
before the sessions of irradiation. The results revealed that topical khellin repigmented vitiligo skin, 
but the khellin-treated patches repigmented no better than those patches treated with vehicle and 
UV A light only. It would therefore appear that the repigmentation observed in khellin-treated 
patches was primarily due to the UV A irradiation component of the photochemotherapy sessions. 
An explanation for the ineffectiveness of khellin in the aqueous cream formulation in the study of 
Procaccini and co-workers is possibly due to the poor solubility of the drug in this type of vehicle, 
as demonstrated in the present study. A consequence of this, is a poor delivery of the drug to the 
target cells. The absence of repigmentation with PYR is possibly explained by the increase in 
solubility ofkhellin in PYR, which may result in higher doses or almost all of the khellin being 
delivered to the epidermal melanocytes and adjacent cells. A cytotoxic dose ofkhellin is thus 
delivered to the cells resulting in their destruction. This probability seems likely since the 
concentration ofkhellin used in the study of Procaccini et. al. (1995) was 240-fold more than the 
concentration ofkhellin (0.5mM and more) shown to be cytotoxic to both melanocytic and non-
melanocytic cells in the present study. Furthermore, an absence of repigmentation could also have 
resulted from UV A-damage of the skin cells. Procaccini et. al. (1995) suggested that this may have 
arisen from the emollient action ofPYR on the skin, which decreases the barrier effect of the 
stratum comeum, and thus more UV A light is able to penetrate through the skin layers. 
Another question to be considered is the apparent cytotoxic effect ofkhellin on cultured fibroblasts. 
One possibility is that the cytotoxic effect on fibroblasts in culture is an experimental artefact and 
only pertains to in vitro studies because fibroblasts grow so much faster in vitro than in vivo. 
Fibroblasts residing in the dermis are not highly proliferative and are therefore less likely to be 
adversely affected by low doses of khellin ( especially since this present study demonstrated 
minimal inhibition). The effect ofkhellin on dermal fibroblasts will need to be determined. 
Another concern regarding KUV A treatment is the potentially damaging effects of UV A light on 
collagen synthesis and turnover. UV A can penetrate into the dermis of the skin because of its long 




A technical limitation of the present study was the inability to detect the rate-limiting enzyme of 
melanogenesis, tyrosinase, in KUV A-treated Mel-1 melanoma cells by western blotting analyses, 
despite a 200% increase in the melanogenic rate of these cells above the untreated cells. This is 
possible because the antibody a.-PEP 7, recognizes mouse rather than human tyrosinase (V. 
Hearing, pers. comm.). Davids (1997), has previously demonstrated that tyrosinase is expressed in 
Mel-1 cells, but at very low levels. For future studies, much longer incubation times with this 
antibody are possibly needed in order to detect this melanogenic protein in human samples. 
Alternatively, other antibodies against human tyrosinase and TRP-1 would be helpful. 
When the melanogenic assays were carried out, the following useful finding was also made. At the 
start ofthis study, the harvested protein from the cultured cells was collected in complete extraction 
buffer (CEB) and the same sample was then used for both enzyme assays and western blot analyses. 
Out of interest, a comparison oflysates prepared in CEB with lysates made in phosphate buffer 
containing 0.5% Triton-X 100 was carried out. The results demonstrated that the incorporation 
values of samples prepared in Triton-X containing phosphate buffer were almost double the values 
of those prepared in CEB buffer (Table 1). It is likely that SDS, which is found within the CEB 
buffer, inhibited the activity oftyrosinase. It was also interesting to note that the phosphate buffer 
in which protease inhibitors had been added, had lower incorporation values than that found with 
the Triton-X containing phosphate buffer alone. This suggests that protease inhibitors had an 
inhibitory effect on tyrosinase activity. It should be noted that the percentage increase in the cpm 
values above the control, were comparable with the different protein lysis buffers, although the 
values obtained with Triton-X containing buffer were much higher. 
TABLE 1. 
TRITOX-X 100 TRITON-X 100 WITH *CEB 
"'P.L 
CPM VALUE+/- S.D. 11518 +/- 1578 7207+/- 891 6541+/- 1921 
'l'P.I. = protease inhibitors (see appendix) 
*CEB (complete extraction buffer) contains P.I. (see appendix) 
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LIMITATIONS OF THE STUDY 
At the commencement of this present study, the experiments were designed to mimic the in vivo 
treatments as far as possible. Several limitations of this study have been identified and these will be 
discussed below: 
Absence of adjacent epidermal cells: In this in vitro study, melanocytes were isolated from other 
epidermal cells, which are normally present in vivo. Thus, the paracrine effects of neighbouring 
cells were not tested after treatment with khellin or KUV A As shown in previous studies with 
PUV A and UV light, both melanocyte proliferation and melanogenesis were increased as a result of 
these agents acting on adjacent keratinocytes, which responded by increasing the release of 
melanogenic and mitogenic growth factors (Halaban et. al., 1987; Imokawa et. al., 1992; Abdel-
Nasser et. al., 1997). Thus, it is possible that the levels of both proliferation and pigmentation of 
KUV A-treated melanocytes in this in vitro tissue culture system might have been increased even 
further if co-cultures of melanocytes and keratinocytes were used. Future experiments could 
therefore be carried out with epidermal constructs, whole skin organ cultures or the melanocytes 
cultured in KUV A-treated keratinocyte-conditioned medium. In this way, paracrine effects of 
KUV A on neighbouring cells could be evaluated. 
A mixed culture of normal human melanocytes from different racial groups: Since normal 
human melanocytes from patients of different racial groups were cultured together, it is not possible 
to make deductions about the responsiveness of melanocytes from different skin types to KUV A 
treatment. Future studies should include melanocyte cultures from patients with the same skin type. 
Single venus multiple UV A irradiations: During KUV A treatment in vivo, patients are exposed 
to multiple irradiations of UV A light or solar irradiation after being treated with topical or oral 
khellin (Milne et. al., 1999). However, in the present study, the melanocytes and melanoma cells 
were exposed to a single dose ofUV A light, as previously described by Kao and Yu, (1992), who 
exposed their cultured melanocytes to PUVA photochemotherapy. Mengeaud and Ortonne, (1996), 
suggested that multiple UV A irradiations were not necessary for stimulating melanogenesis in vitro 
when melanocytes were cultured in the presence of melanocytic mitogens such as TP A ( a phorbol 
ester). Since mitogens were present in the culture medium of the normal human melanocytes, it 
was decided to use a single UV A dose for this study. In addition, since a melanogenic response was 
obtained with this single UV A dose, it was decided not to pursue the investigation in which the 
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effects of multiple UV A irradiations on the melanocytes would be determined. It is quite possible 
that if multiple UV A irradiation doses were used in the present culture system, more significant 
differences would have been detected. 
Melanocyte migration: It is not known whether the increase in melanocyte proliferation observed 
after KUV A treatment will necessarily lead to an increase in the melanocyte migration or whether 
KUV A actually stimulates the migration of these melanocytes directly. An increase in both the 
processes of proliferation and migration of melanocytes are clearly needed to repopulate the 
depigmented vitiligo skin to restore skin colour in patients. In this study, however, melanocyte 
migration studies were not carried out. Future work would therefore include migration studies by 
means ofimmunocytochemistry or Boyden chamber assays (Horikawa et. al., 1995), in order to 
determine whether KUVA treatment affects melanocyte migration. 
CONCLUSION AND GENERAL COMMENTS 
Khellin alone and in combination with UV A (KUV A), directly stimulates proliferation as well as 
the pigment-forming ability of both normal human melanocytes and human melanoma cells in 
culture. Unlike PUV A. KUY A treatment does not rely on paracrine factors from adjacent 
epidermal cells to bring about these increases in the biological processes of proliferation and 
melanogenesis. Importantly, the most effective dose ofkhellin is O.OlmM, which is 20,000 fold 
lower than the dose currently used (200mM) to make up the cream for clinical trials. Therefore, 
lower doses than currently employed, combined with a more effective way to dissolve the drug, 
would possibly be more efficacious than the current treatment regimen. This possibility is 
supported by the recent clinical trials carried out by Milne et. al., (1999). These investigators 
demonstrated that more effective repigmentation was obtained with lower khellin doses. This 
ensures that the optimal dose is delivered to the cells, and therefore adverse effects would be 
minimized. Since the present study also showed that khellin and KUV A treatment inhibit the 
proliferation of fibroblasts, this suggests that KUV A acts on signalling pathways exclusive to 
melanocytes, possibly via the endothelin-1 pathway. 
Future studies 
• Carrying out drug trials using lower doses of drug in a suitable carrier vehicle. These studies 
could be combined with histological studies to determine for example, c-kit receptor expression 
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of KUV A-treated skin biopsies. 
• Investigating in greater detail the mechanism of khellin action ( signalling and downstream 
events). For example, in order to determine whether ET-1 and KUV A share the same signalling 
pathway, antagonists for the PKC, PKA and MAP kinase signal transduction pathways could be 
used. 
• Co-culturing of keratinocytes and melanocytes, or melanocyte cultures with keratinocyte-
conditioned medium, would pr~vide clues regarding the paracrine effects of khellin and KUV A. 
• Testing khellin and KUV A on an animal model for vitiligo (for example Mitj' mutant mouse, 
Bora et. al., 1999) with an intact epidermal environment and normal immune system. The same 
model is later then to be used for applying the newly formulated khellin cream. This is to be 
followed by pharmacokinetic studies, to determine whether the optimal khellin dose is being 
delivered to the melanocytes. This model will also give an indication of adverse effects likely 
to be experienced with this cream formulation. 
Finally, the information obtained from this cell biological study provides support for more extensive 
studies to be carried out by dermatologists with KUV A photochemotherapy. This study also 
emphasizes the need for work on investigating the transdermal delivery of the most effective doses 
ofkhellin to the target melanocytes, in view of its potential in vitro melanocytoxicity. 
APPENDIX 
SOLUTIONS: 





pH to 7.4 and made up to one litre with distilled water. 
Autoclaved to sterilize. 
O.lM PHOSPHATE BUFFER (pH 7.4) 
NafhPO~H20 
Na2HP04.2H20 
15.6g dissolve in 1 litre water ... solution A 
17.8g dissolve in 1 litre water. .. solution B 
Made up solution A and solution B, by dissolving salts with magnetic stirrer bar. Added 200ml 
solution A to 800ml solution B (1 :4) and pH to 7.4. 
TISSUE CULTURE REAGENTS: 
HAM'S F-10 CULTURE MEDIUM (1 LITRE) 
10g Ham's F-10 powder (Highveld Biological) 
1.2g NaHC03 
pH to 7.2 and made up to 1 litre with distilled water. 
Filter sterilize with 0.22µm filter unit 
BRL-CONDIDONED MEDIUM 
Ham' s F-10 culture medium 
20% Heat inactivated foetal calf serum 
1% Penicillin/Streptomycin (100IU penicillin/ 100mg/ml streptomycin) 
0.1 % Fungizone 
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5mM IBMX (Isomethylbutylxanthine) 
TPA (40µM working solution, use 5µ1/ml) 
Insulin (1 OOIU/ml) 
Cholera Toxin (2µ1/ml) 
Penicillin/Streptomycin ( 1 % ) 
Fungizone 
HOECHST STAIN 33342: BISBENZIMIDAZOLE DYE 
SOLUTIONS: 
(1 ) ACETIC ACID/ METHANOL (1:2) 
Mixed 30ml glacial acetic acid (BDH), with 60ml methanol (Merck) 
Hank's Balanced Salt Solution (HBSS) 100ml 
HANK'S BALANCED SALT SOLUTION (HBSS) lOOML 





0.09g NazHP04. 7H20 
0.06g KH2P04 
lg glucose 
Dissolved in 80ml distilled water. 
Solution 2: 
Dissolved 0.14g CaCh in 10ml distilled water 
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Solution 3: 
Dissolved 0.02g phenol red in 5ml distilled water 
Combined solutions 1 and 3. Added slowly to this, was solution 2 and water to a final volume of 
100ml. Chloroform (500µ1) was added a preservative. 
(3) HOECHST POWDER STOCK SOLUTION (lmg/ml) 
Weighed 0.001g powder and added 1ml HBSS. Stored stock at 4°C in dark, covered with foil. 
( 4) HOECHST WORKING SOLUTION (lng/ml) 50ml 
Take 50µ1 of lmg/ml Hoechst stock solution, and added 50ml HBSS 
(5) MOUNTING MEDIUM: VERONAL BUFFERED GLYCERINE 
VERONAL BUFFER: 
0.51g veronal sodium (barbitone sodium) 
0.31g NaCl 
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Added 40ml distilled water and stirred for 5 minutes with a magnetic stirrer. Made up to 50ml with 
distilled water. pH to 8.6 with IN HCL. Thereafter, mixed equal quantities ofveronal buffer (pH 
8.6) with glycerine (50ml). Stored at 4°C, until used. 
PROTOCOL FOR MYCOPLASMA DETECTION 
(1) A day or more before experiment was started, plated cells onto a sterile coverslip within a 
35mni2 dish (Corning). Allowed the cells to reach a density of 60-65% confluency on the 
coverslip. 
(2) Rinsed cells twice with HBSS (2ml for each wash) 
Added 1ml HBSS and 1ml acetic/methanol (1:3) solutions to petri dish. Rocked the petri 
dish and discarded the solution into disposable waste container. 
Added 2ml acetic acid/methanol (1 :3) solution to the dish. Rocked the dish and discarded 
the solution. 
(5) Added 2ml acetic acid/methanol (1:3) solution to dish and left for ten minutes at room 
temperature 
(6) Discarded acetic acid /methanol (1:3) and washed twice with HBSS 
(7) Added 2ml Hoechst working solution (Ing/ml) and left for ten minutes at room temperature 
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(8) Discarded Hoechst solution into disposable waste tube and into radioactive waste 
(9) Rinsed thrice with 2ml HBSS 
(10) Placed a drop ofveronal mounting medium on to a glass slide and placed the coverslip, with 
cell side down onto the coverslip. 
(11) Left for one hour at 37°C in a humidity chamber or leave at room temperature overnight. 
(12) Viewed under fluorescent microscope for signs of fluorescence, indicative of mycoplasmal 
contamination. 






IM Tris-HCI, pH7.2 
100% Nonidet P-40 (nonionic detergent) 
. 10% SDS (Sodium dodecyl sulphate) 
distilled water 
Filter sterilized with 0.22µm and stored at 4°C for six months 
CEB PREPARATION 
Added the following reagents on ice: 
10ml extraction buffer 
10µ1 Aprotinin (lmg/ml stock)* 
10µ1 PMSF (phenyl methylsulfonyl-flouride)cl) 
* (Aprotinin (lmg/ml stock) 
10mg powder added to 10ml sterile distilled water. Aliquotted into sterile Eppendorfs and stored at 
-20°C 
cl)(PMSF) 
Weighed out 0.087mg PMSF powder and added 5ml isopropanol. Shook until all crystalline 
powder is dissolved completely. Stored in dark bottle at room temperature on shelf 
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PROTEIN ASSAY PROTOCOLS 
BCA PROTEIN ASSAY 
Pipetted 1 Oµl of sample + 40µ1 0 .1 M phosphate buffer (pH 7.4) or 50µ1 standards into Eppendorf 
tubes in triplicates. 50µ1 of 0.1 M phosphate buffer was pipetted into the tube as the blank. The 
standards were prepared from a 2mg/ml stock of bovine serum albumin. 
Added 1ml BCA working reagent to each tube and mixed well 
Incubated all the tubes for 30 minutes in a 37°C waterbath. 
After incubation, cooled the tubes at room temperature for 5 minutes 
Measured the absorbance at 562 nm of each tube against the blank as the reference tube. 
Prepared a standard curve by plotting the ~562) reading for each standard versus its concentration in 
mg/ml. Used the standard curve in order to determine the protein concentration of the unknown 
samples. 
The samples were all standardised to the lowest protein concentration. 
BIO-RAD PROTEIN ASSAY PROTOCOL 
(i) Prepared several dilutions of protein standards, using 2mg/ml bovine serum albumin as the 
stock protein solution. All samples were prepared in duplicates. 
(ii) Placed 20µ1 of the diluted sample, having taken into account the dilution factor, and placed 
20µ1 of standards into 2ml sterile Eppendorfs. Placed 20µ1 of O. lM phosphate buffer into 
the ''blank" Eppendorf 
(iii) Added 1ml dilute dye reagent (dye: water, 1:50) to each Eppendorf 
(iv) Vortexed or mixed several times by gentle inversion of test tube. 
(v) Allowed samples to stand on bench-top for 15 minutes 
(vi) Measured samples spectrophotometrically 0Dcs95) versus the blank reagent 
(vii) Plotted 0Dc595) versus the concentration of standards in µg/ml. 
(viii) The unknown protein sample concentrations could be determined from the graph. 
(ix) The samples were then all standardised to the lowest protein concentration. 
3H-THYMID1NE INCORPORATION ASSAY 
(i) After the cells were incubated with 3H-thymidine (5µCi/ml), in the presence or absence of 
khellin for 48 hours, the radioactive medium was aspirated. 
(ii) The cells were washed twice with serum-free medium (sfm) or PBS. 
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(iii) The sfm was aspirated and the cells were washed thrice with ice-cold 10% TCA 
(trichloroacetic acid, BDH) for 5 minutes per wash, on an ice-tray, to assist the precipitation 
of the labelled DNA 
(iv) TCA was then aspirated in order to remove the free (unincorporated) thymidine. 
The cells were washed once with 10% (/v) SDS for 2 minutes at room temperature to 
solubilize the cell membranes and release the TCA precipitate. 
The solubilized precipitate was placed into 5ml liquid scintillating cocktail and the 
radioactivity levels were determined with a liquid scintillating counter. 
An example of raw data obtained from a typical 1"C-tyrosine assay 
Khellin concentration (mM) CPM values obtained with CPM values obtained with 
normal human melanocytes Mel-1 cells exposed to khellin 
exposed to khellin 
0 8849 3695 
0.01 22855 10177.5 
0.1 18848 8095 
' J 
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